



[www.MedChemExpress.com](http://www.MedChemExpress.com)











Inhibitors, Screening Libraries, Proteins











# Adrenergic Receptor

## Beta Receptor

Adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially norepinephrine and epinephrine. Many cells possess these receptors, and the binding of a catecholamine to the receptor will generally stimulate the sympathetic nervous system. The sympathetic nervous system is responsible for the fight-or-flight response, which includes widening the pupils of the eye, mobilizing energy, and diverting blood flow from non-essential organs to skeletal muscle. There are two main groups of adrenergic receptors,  $\alpha$  and  $\beta$ , with several subtypes.  $\alpha$  receptors have the subtypes  $\alpha_1$  and  $\alpha_2$ .  $\beta$  receptors have the subtypes  $\beta_1$ ,  $\beta_2$  and  $\beta_3$ . All three are linked to Gs proteins, which in turn are linked to adenylate cyclase. Agonist binding thus causes a rise in the intracellular concentration of the second messenger cAMP. Downstream effectors of cAMP include cAMP-dependent protein kinase (PKA), which mediates some of the intracellular events following hormone binding.

## Adrenergic Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators


<p><b>(+)-Penbutolol</b> (R)-Penbutolol; (+)-Isoprenbutolol</p> <p>Cat. No.: HY-116790A</p> <p>(+)-Penbutolol is a <math>\beta</math>-adrenoceptor antagonist, with an <math>IC_{50}</math> of 0.74 <math>\mu</math>M. (+)-Penbutolol is an optical isomer of l-penbutolol with <math>Na^+</math> channel-blocking action.</p>  <p><b>Purity:</b> <math>\geq 95.0\%</math> <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>(4E)-SUN9221</b></p> <p>Cat. No.: HY-U00367</p> <p>(4E)-SUN9221 is a potent antagonist of <math>\alpha 1</math>-adrenergic receptor and 5-HT<sub>2</sub> receptor, with antihypertensive and anti-platelet aggregation activities.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>(R)-(+)-Atenolol</b></p> <p>Cat. No.: HY-B2111</p> <p>(R)-(+)-Atenolol is the less active enantiomer of the (R,S)-atenolol. (R,S)-atenolol is a <math>\beta</math>-adrenergic receptor antagonist.</p>  <p><b>Purity:</b> <math>\geq 99.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>	<p><b>(R)-Carvedilol</b> (R)-BM 14190</p> <p>Cat. No.: HY-B0006C</p> <p>(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective <math>\beta/\alpha</math>-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).</p>  <p><b>Purity:</b> 99.05% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>
<p><b>(R)-Carvedilol-d4</b> (R)-BM 14190-d4</p> <p>Cat. No.: HY-B0006CS</p> <p>(R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective <math>\beta/\alpha</math>-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> <b>Size:</b> 1 mg, 5 mg</p>	<p><b>(R)-Metoprolol-d7</b></p> <p>Cat. No.: HY-17503S1</p> <p>(R)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective <math>\beta</math>1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>
<p><b>(R)-Propranolol hydrochloride</b></p> <p>Cat. No.: HY-A0295</p> <p>(R)-Propranolol hydrochloride is a less active enantiomer of the <math>\beta</math>-adrenoceptor antagonist propranolol (HY-B0573).</p>  <p><b>Purity:</b> 99.36% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg</p>	<p><b>(R)-Terazosin</b></p> <p>Cat. No.: HY-B0371B</p> <p>(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent <math>\alpha 1</math>-adrenoceptor antagonist with <math>K_i</math> values of 6.51 nM, 1.01 nM and 1.97 nM for <math>\alpha 1a</math>, <math>\alpha 1b</math> and <math>\alpha 1d</math>-adrenoceptor, respectively.</p>  <p><b>Purity:</b> 99.77% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>(rac)-Dobutamine-d4 hydrochloride</b></p> <p>Cat. No.: HY-15746S</p> <p>(Rac)-Dobutamine-d4 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on <math>\alpha 1</math>-AR, <math>\beta 1</math>-AR, <math>\beta 2</math>-AR (<math>\alpha</math>-1, <math>\beta</math>-1 and <math>\beta</math>-2 adrenoceptors).</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> <b>Size:</b> 2.5 mg, 1 mg, 10 mg, 25 mg</p>	<p><b>(rac)-Dobutamine-d6 hydrochloride</b></p> <p>Cat. No.: HY-15746S1</p> <p>(Rac)-Dobutamine-d6 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on <math>\alpha 1</math>-AR, <math>\beta 1</math>-AR, <math>\beta 2</math>-AR (<math>\alpha</math>-1, <math>\beta</math>-1 and <math>\beta</math>-2 adrenoceptors).</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>



### (S)-Metoprolol-d7

Cat. No.: HY-17503S2

(S)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective  $\beta_1$  receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 10 mg

### (S)-Phenylephrine-d6 hydrochloride

Cat. No.: HY-B0471S2

(S)-Phenylephrine-d6 (hydrochloride) is deuterium labeled Phenylephrine (hydrochloride). (R)-(-)-Phenylephrine hydrochloride is a selective  $\alpha_1$ -adrenoceptor agonist with pKis of 5.86, 4.87 and 4.70 for  $\alpha_1D$ ,  $\alpha_1B$  and  $\alpha_1A$  receptors respectively.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### (S)-Terazosin

Cat. No.: HY-B0371D

(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity  $\alpha$ -adrenoceptor antagonist with  $K_i$  values of 3.91 nM, 0.79 nM and 1.16 nM for  $\alpha_1a$ ,  $\alpha_1b$  and  $\alpha_1d$ -adrenoceptor, respectively.




**Purity:** 99.77%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### (S)-Timolol Maleate

(L-714,465 Maleate; MK 950)

Cat. No.: HY-17380

(S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic  $\beta$ -adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor.




**Purity:** 99.85%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 100 mg, 200 mg

### (S)-Timolol-d9 maleate

(L-714,465-d9 maleate; MK 950-d9)

Cat. No.: HY-17380S

(S)-Timolol-d9 (maleate) is deuterium labeled (S)-Timolol (Maleate). (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic  $\beta$ -adrenoceptor blocker.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### ( $\pm$ )-Befunolol

Cat. No.: HY-101752

( $\pm$ )-Befunolol is a  $\beta$ -adrenoceptor blocking agent.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### ( $\pm$ )-Penbutolol-d9 hydrochloride ((Rac)-Penbutolol-d9 hydrochloride; ( $\pm$ )-Isoprenbutolol-d9 hydrochloride)

Cat. No.: HY-116790BSA

( $\pm$ )-Penbutolol-d9 ((Rac)-Penbutolol-d9) hydrochloride is a deuterium labeled ( $\pm$ )-Penbutolol hydrochloride. (+)-Penbutolol hydrochloride is a  $\beta$ -adrenoceptor antagonist, with an  $IC_{50}$  of 0.74  $\mu$ M.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg

### 2',5'-Dideoxyadenosine

Cat. No.: HY-135878

2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor via binding the P-site with an  $IC_{50}$  of 3  $\mu$ M. 2',5'-Dideoxyadenosine is a nucleoside analog and exerts a potent antiadrenergic action in heart.




**Purity:** 99.86%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

### 2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride)

Cat. No.: HY-103197

2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride) is a highly selective  $\alpha$ 2-adrenoceptor antagonist with little or no imidazoline antagonist effect.




**Purity:** 99.20%  
**Clinical Data:** No Development Reported  
**Size:** 10 mg, 50 mg, 100 mg









### 4-Hydroxypropranolol hydrochloride (( $\pm$ )-4-hydroxy Propranolol hydrochloride)











Cat. No.: HY-100634

4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol. 4-Hydroxypropranolol hydrochlorid is of comparable potency to Propranolol.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg











<p><b>4-Hydroxypropranolol-d7</b> (±)-4-Hydroxy Propranolol-d7</p> <p>Cat. No.: HY-100634SA</p> <p>4-Hydroxypropranolol-d7 ((±)-4-Hydroxy Propranolol-d7) is the deuterium labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>4-Hydroxypropranolol-d7 hydrochloride</b> (±)-4-Hydroxy Propranolol-d7 hydrochloride</p> <p>Cat. No.: HY-100634S</p> <p>4-Hydroxypropranolol D7 hydrochloride ((±)-4-hydroxy Propranolol D7 hydrochloride) is a deuterium labeled 4-Hydroxypropranolol hydrochloride.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>5-HT2 antagonist 1</b></p> <p>Cat. No.: HY-U00365</p> <p>5-HT2 antagonist 1 is a potent antagonist of 5-HT2 receptor, with weak <math>\alpha 1</math> adrenoceptor blocking activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>A-61603</b></p> <p>Cat. No.: HY-101366</p> <p>A-61603 is a selective <math>\alpha_{1A}</math>-adrenergic receptor agonist. A-61603 increases the frequency of spontaneous <math>Ca^{2+}</math> transients in rat ventricular myocytes in vitro.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>A55453</b></p> <p>Cat. No.: HY-111188</p> <p>A55453 is a prazosin analogue and a potent <math>\alpha 1</math>-adrenergic antagonist. <math>^{125}I</math>-A55453 is a high-affinity alpha 1-adrenergic receptor probe.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Aaptamine</b></p> <p>Cat. No.: HY-N4225</p> <p>Aaptamine, a spongean alkaloid isolated from a sea sponge Aaptos aaptos, is a competitive antagonist of <math>\alpha</math>-adrenoceptor and activates the p21 promoter in a p53-independent manner.</p>  <p><b>Purity:</b> 99.16% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Acebutolol D7</b></p> <p>Cat. No.: HY-17497S</p> <p>Acebutolol D7 is a deuterium labeled Acebutolol. Acebutolol is a selective <math>\beta 1</math> adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Acebutolol hydrochloride</b></p> <p>Cat. No.: HY-17497A</p> <p>Acebutolol hydrochloride is a <math>\beta 1</math> adrenergic receptor (<math>\beta 1AR</math>) antagonist. Acebutolol hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.</p>  <p><b>Purity:</b> 99.95% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>
<p><b>ACTH (1-14)</b> (Adrenocorticotrophic Hormone Fragment 1-14)</p> <p>Cat. No.: HY-P1582</p> <p>ACTH (1-14) is a fragment of adrenocorticotrophin, which regulates cortisol and androgen production.</p> <p>SYSMEHFRWGKPVG</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>ACTH (1-14) (TFA)</b> (Adrenocorticotrophic Hormone Fragment 1-14 TFA)</p> <p>Cat. No.: HY-P1582A</p> <p>ACTH (1-14) (TFA) is a fragment of adrenocorticotrophin, which regulates cortisol and androgen production.</p> <p>SYSMEHFRWGKPVG (TFA salt)</p> <p><b>Purity:</b> 98.55% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>











<p><b>ADRA1D receptor antagonist 1</b></p> <p>Cat. No.: HY-135270</p> <p>ADRA1D receptor antagonist 1 is a potent, selective and orally active <math>\alpha_{1D}</math> adrenoceptor antagonist, with a <math>K_i</math> of 1.6 nM.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>AGN 192836</b></p> <p>Cat. No.: HY-100300</p> <p>AGN 192836 is a potent and selective <math>\alpha_2</math> adrenergic agonist with <math>EC_{50}</math>s of 8.7, 41 and 6.6 nM for <math>\alpha_2A</math>, <math>\alpha_2B</math> and <math>\alpha_2C</math> receptor, respectively.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Ajmalicine</b> (Raubasine)</p> <p>Cat. No.: HY-N1919</p> <p>Ajmalicine (Raubasine) is found in herbs of Catharanthus roseus, is an antihypertensive drug used in the treatment of high blood pressure, decreases peripheral resistance and blood pressure.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Alfuzosin</b> (SL 77499)</p> <p>Cat. No.: HY-B0192</p> <p>Alfuzosin is an <math>\alpha_1</math> adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).</p>  <p><b>Purity:</b> 99.67%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>
<p><b>Alfuzosin hydrochloride</b> (SL 77499-10)</p> <p>Cat. No.: HY-B0192A</p> <p>Alfuzosin hydrochloride is an <math>\alpha_1</math> adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).</p>  <p><b>Purity:</b> 98.73%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p><b>Alfuzosin-13C,d3</b> (SL 77499-13C,d3)</p> <p>Cat. No.: HY-B0192S1</p> <p>Alfuzosin-13C,d3 is the 13C- and deuterium labeled.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Alfuzosin-d3</b> (SL 77499-d3)</p> <p>Cat. No.: HY-B0192S2</p> <p>Alfuzosin-d3 is deuterium labeled Alfuzosin.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Alfuzosin-d3 hydrochloride</b></p> <p>Cat. No.: HY-B0192AS</p> <p>Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an <math>\alpha_1</math> adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Alfuzosin-d7 hydrochloride</b> (SL 77499-10-d7)</p> <p>Cat. No.: HY-B0192AS1</p> <p>Alfuzosin-d7 hydrochloride (SL 77499-10-d7) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an <math>\alpha_1</math> adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Amezinium methylsulfate</b> (Amezinium metilsulfate; Lu-1631)</p> <p>Cat. No.: HY-A0275</p> <p>Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition of noradrenaline and tyramine uptake.</p>  <p><b>Purity:</b> 99.51%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg, 1 g</p>











<p><b>Amibegron hydrochloride</b> (SR 58611A)</p> <p>Amibegron hydrochloride is a selective <math>\beta_3</math>-adrenoceptor agonist, with an <math>EC_{50}</math> of 3.5 nM for <math>\beta</math>-adrenoceptor in rat colon; Amibegron hydrochloride has anxiolytic and antidepressant activity.</p> <p><b>Purity:</b> <math>\geq 98.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg</p>	<p><b>Amitraz</b> (BTS-27419)</p> <p>Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.</p> <p><b>Purity:</b> <math>\geq 95.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>
<p><b>Amitraz-d6</b> (BTS-27419-d6)</p> <p>Amitraz-d6 (BTS-27419-d6) is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Amitriptyline hydrochloride</b></p> <p>Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with <math>K_i</math>s of 3.45 nM and 13.3 nM for human SERT and NET, respectively.</p> <p><b>Purity:</b> 99.56% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g</p>
<p><b>Amitriptyline-d3 hydrochloride</b></p> <p>Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride).</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 1 mg, 5 mg, 10 mg</p>	<p><b>Amitriptyline-d6 hydrochloride</b></p> <p>Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 1 mg, 5 mg, 25 mg</p>
<p><b>Ancarolol</b></p> <p>Ancarolol is a <math>\beta</math>-adrenergic blocking agent.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>AR-08</b></p> <p>AR-08 is an agonist of <math>\alpha_2</math>-adrenergic receptor, used for the treatment of attention deficit hyperactivity disorder (ADHD).</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> Phase 2 <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Arbutamine</b></p> <p>Arbutamine is a short-acting, potent and nonselective <math>\beta</math>-adrenoceptor agonist that increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine is a catecholamine for a pharmacological cardiac stress agent.</p> <p><b>Purity:</b> <math>\geq 98.0\%</math> <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg</p>	<p><b>Arotinolol</b></p> <p>Arotinolol is a nonselective <math>\alpha/\beta</math>-adrenergic receptor blocker and a vasodilating <math>\beta</math>-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand <math>^{125}I</math>-ICYP to <math>5HT_{1B}</math>-serotonergic receptor sites.</p> <p><b>Purity:</b> 98.23% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg</p>











<p><b>Asenapine</b> (Org 5222)</p> <p>Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of <b>serotonin receptors</b> (pK<sub>i</sub>: 8.4-10.5), <b>adrenoceptors</b> (pK<sub>i</sub>: 8.9-9.5), <b>dopamine receptors</b> (pK<sub>i</sub>: 8.9-9.4) and <b>histamine receptors</b> (pK<sub>i</sub>: 8.2-9.0).</p> <p><b>Purity:</b> 98.81% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p><b>Asenapine-d3</b> (Org 5222-d3)</p> <p>Asenapine-d3 (Org 5222-d3) is the deuterium labeled Asenapine.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Asenapine-d7</b> (Org 5222-d7)</p> <p>Asenapine-d7 (Org 5222-d7) is the deuterium labeled Asenapine.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Atenolol</b> (<i>(RS)</i>-Atenolol)</p> <p>Atenolol (<i>(RS)</i>-Atenolol) is a cardioselective <math>\beta_1</math>-adrenergic receptor blocker, with a K<sub>i</sub> of 697 nM at <math>\beta_1</math>-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.</p> <p><b>Purity:</b> 99.61% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g</p>
<p><b>Atenolol-d7</b> (<i>(RS)</i>-Atenolol-d7)</p> <p>Atenolol-d7 (<i>(RS)</i>-Atenolol-d7) is the deuterium labeled Atenolol. Atenolol (<i>(RS)</i>-Atenolol) is a cardioselective <math>\beta_1</math>-adrenergic receptor blocker, with a K<sub>i</sub> of 697 nM at <math>\beta_1</math>-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Atipamezole</b> (MPV 1248)</p> <p>Atipamezole (MPV 1248) is a potent <math>\alpha_2</math>-adrenoceptor antagonist with a K<sub>i</sub> of 1.6 nM.</p> <p><b>Purity:</b> 99.48% <b>Clinical Data:</b> Phase 1 <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>
<p><b>Atipamezole hydrochloride</b> (MPV-1248 hydrochloride)</p> <p>Atipamezole (MPV-1248) hydrochloride is a potent <math>\alpha_2</math>-adrenoceptor antagonist with a K<sub>i</sub> of 1.6 nM.</p> <p><b>Purity:</b> 99.41% <b>Clinical Data:</b> Phase 1 <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>	<p><b>Atomoxetine-d3 hydrochloride</b></p> <p>Atomoxetine-d3 hydrochloride is a potent <math>\alpha_2</math>-adrenoceptor antagonist with a K<sub>i</sub> of 1.6 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Azepexole dihydrochloride</b> (B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride)</p> <p>Azepexole (B-HT 933) dihydrochloride is a potent and selective <b>alpha 2-adrenoceptor</b> agonist with pK<sub>i</sub>s of 8.3, 7.6, and 7.5 for <math>\alpha_2A</math>-, <math>\alpha_2B</math>- and <math>\alpha_2C</math>-adrenoceptor subtypes, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Bambuterol</b> (<math>\pm</math>)-Bambuterol; KWD-2183)</p> <p>Bambuterol (<math>\pm</math>)-Bambuterol; KWD-2183) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 25 mg</p>






















<p><b>Bambuterol hydrochloride</b> (±)-Bambuterol hydrochloride; KWD-2183 hydrochloride) <b>Cat. No.:</b> HY-17501A</p> <p>Bambuterol hydrochloride ((±)-Bambuterol hydrochloride; KWD-2183 hydrochloride) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.</p> <p><b>Purity:</b> 99.64% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p> 	<p><b>Bambuterol-d9 hydrochloride</b> ((±)-Bambuterol-d9 hydrochloride; KWD-2183-d9 hydrochloride) <b>Cat. No.:</b> HY-17501S</p> <p>Bambuterol-D9 ((±)-Bambuterol-D9) hydrochloride is the deuterium labeled Bambuterol. Bambuterol ((±)-Bambuterol) hydrochloride is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p> 
<p><b>Batefenterol</b> (GSK961081; TD-5959) <b>Cat. No.:</b> HY-12980</p> <p>Batefenterol (GSK961081;TD-5959) is a novel muscarinic receptor antagonist and β<sub>2</sub>-adrenoceptor agonist; displays high affinity for hM2, hM3 muscarinic and hβ<sub>2</sub>-adrenoceptor with K<sub>i</sub> values of 1.4, 1.3 and 3.7 nM, respectively.</p> <p><b>Purity:</b> 98.08% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Benzquinamide</b> (P2647; BZQ; Benzoquinamide) <b>Cat. No.:</b> HY-U00244</p> <p>Benzquinamide (P2647) is an antiemetic which can bind to the α<sub>2A</sub>, α<sub>2B</sub>, and α<sub>2C</sub> adrenergic receptors (α<sub>2</sub>-AR) with K<sub>i</sub> values of 1,365, 691, and 545 nM, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Benzquinamide-d3 hydrochloride</b> <b>Cat. No.:</b> HY-U00244S</p> <p>Benzquinamide-d3 hydrochloride is the deuterium labeled Benzquinamide hydrochloride. Benzquinamide (P2647) is an antiemetic which can bind to the α<sub>2A</sub>, α<sub>2B</sub>, and α<sub>2C</sub> adrenergic receptors (α<sub>2</sub>-AR) with K<sub>i</sub> values of 1,365, 691, and 545 nM, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 25 mg</p> 	<p><b>Besipirdine</b> (HP 749 free base) <b>Cat. No.:</b> HY-15376</p> <p>Besipirdine is a non-receptor-dependent cholinomimetic agent with noradrenergic activity. Besipirdine inhibits voltage-dependent sodium and potassium channels.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Betaxolol</b> <b>Cat. No.:</b> HY-B0381</p> <p>Betaxolol is a selective beta<sub>1</sub> adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.</p> <p><b>Purity:</b> 95.06% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p> 	<p><b>Betaxolol hydrochloride</b> (SL75212) <b>Cat. No.:</b> HY-B0381A</p> <p>Betaxolol Hydrochloride is a selective beta<sub>1</sub> adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.</p> <p><b>Purity:</b> 98.69% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p> 
<p><b>Betaxolol-d5</b> <b>Cat. No.:</b> HY-B0381S</p> <p>Betaxolol-d5 is the deuterium labeled Betaxolol. Betaxolol is a selective beta<sub>1</sub> adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p> 	<p><b>Betaxolol-d7 hydrochloride</b> (SL75212-d7) <b>Cat. No.:</b> HY-B0381AS</p> <p>Betaxolol-d7 hydrochloride (SL75212-d7) is the deuterium labeled Betaxolol hydrochloride. Betaxolol Hydrochloride is a selective beta<sub>1</sub> adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 











<p><b>Bevantolol</b></p> <p style="text-align: right;">Cat. No.: HY-A0249</p> <p>Bevantolol is a selective <math>\beta</math>-1 adrenoceptor antagonist. Bevantolol can be used for the research of angina pectoris and hypertension.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Bevantolol hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-121186</p> <p>Bevantolol hydrochloride is a selective <math>\beta</math>1 and <math>\alpha</math>1-adrenergic receptor antagonist with <math>pK_i</math> values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent <math>Ca^{2+}</math> antagonist.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 25 mg, 50 mg, 100 mg</p>
<p><b>BI-167107</b></p> <p style="text-align: right;">Cat. No.: HY-121251</p> <p>BI-167107 is a high affinity, full agonist that binds to the <math>\beta</math>2 adrenergic receptor (<math>\beta</math>2AR) with a dissociation constant <math>K_d</math> of 84 pM.</p>  <p><b>Purity:</b> 99.81%  <b>Clinical Data:</b>  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Bisoprolol</b></p> <p style="text-align: right;">Cat. No.: HY-129029</p> <p>Bisoprolol is a potent, selective and orally active <math>\beta</math>1-adrenergic receptor blocker. Bisoprolol has little activity on <math>\beta</math>2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Bisoprolol hemifumarate</b></p> <p style="text-align: right;">Cat. No.: HY-B0076</p> <p>Bisoprolol hemifumarate is a selective <b>type <math>\beta</math>1 adrenergic receptor</b> blocker.</p>  <p><b>Purity:</b> 99.65%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg, 200 mg, 500 mg</p>	<p><b>Bisoprolol-d5</b></p> <p style="text-align: right;">Cat. No.: HY-129029S</p> <p>Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active <b><math>\beta</math>1-adrenergic receptor</b> blocker.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Bisoprolol-d7 hemifumarate</b></p> <p style="text-align: right;">Cat. No.: HY-B0076S</p> <p>Bisoprolol-d7 hemifumarate is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective <b>type <math>\beta</math>1 adrenergic receptor</b> blocker.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Blonanserin</b> (AD-5423)</p> <p style="text-align: right;">Cat. No.: HY-13575</p> <p>Blonanserin (AD-5423) is a potent and orally active 5-HT<sub>2A</sub> (<math>K_i=0.812</math> nM) and dopamine D<sub>2</sub> receptor (<math>K_i=0.142</math> nM) antagonist.</p>  <p><b>Purity:</b> 98.73%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 25 mg, 100 mg</p>
<p><b>BMY 7378</b></p> <p style="text-align: right;">Cat. No.: HY-100554</p> <p>BMY 7378 is a selective antagonist of <math>\alpha_{1D}</math>-adrenoceptor (<math>\alpha_{1D}</math>-AR). BMY 7378 binds to membranes expressing the cloned rat <math>\alpha_{1D}</math>-AR with a &gt;100-fold higher affinity (<math>K_i=2</math> nM) than binding to either the cloned rat <math>\alpha_{1A}</math>-AR (<math>K_i=800</math> nM) or the hamster <math>\alpha_{1B}</math>-AR (<math>K_i=600</math> nM).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>BMY-14802 hydrochloride</b> (BMY-14802-1; BMS 181100 hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-108509</p> <p>BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active <b>sigma receptor</b> antagonist with an <math>IC_{50}</math> of 112 nM. BMY-14802 hydrochloride is also a 5-HT<sub>1A</sub> and <b>adrenergic <math>\alpha</math>1 receptors</b> agonist. BMY-14802 hydrochloride has antipsychotic effects.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>











<p><b>Bometolol Hydrochloride</b></p> <p>Cat. No.: HY-U00386</p> <p>Bometolol Hydrochloride is a <b>beta-adrenergic</b> blocking agent, used for the research of cardiovascular disease.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Bopindolol</b>  <b>((±)-Bopindolol)</b></p> <p>Cat. No.: HY-B1562</p> <p>Bopindolol is an orally active antagonist of <b>β-adrenoceptors (ARs)</b> with partial agonist activity. Bopindolol is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Bopindolol fumarate</b>  <b>((±)-Bopindolol fumarate)</b></p> <p>Cat. No.: HY-B1562C</p> <p>Bopindolol ((±)-Bopindolol) fumarate is an orally active antagonist of <b>β-adrenoceptors (ARs)</b> with partial agonist activity. Bopindolol fumarate is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Brimonidine</b>  <b>(UK 14304; AGN190342)</b></p> <p>Cat. No.: HY-B0659</p> <p>Brimonidine (UK 14304) is a full <b>α2-adrenergic</b> receptor (α2-AR) agonist.</p>  <p><b>Purity:</b> 99.99%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Brimonidine tartrate</b>  <b>(UK 14304 tartrate; AGN190342 tartrate)</b></p> <p>Cat. No.: HY-B0659A</p> <p>Brimonidine tartrate (UK 14304 tartrate) is a full <b>α2-adrenergic</b> receptor (α2-AR) agonist.</p>  <p><b>Purity:</b> 99.19%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p>	<p><b>Brimonidine-d4</b></p> <p>Cat. No.: HY-B0659S</p> <p>Brimonidine-d4 is the deuterium labeled Brimonidine. Brimonidine (UK 14304) is a full <b>α2-adrenergic</b> receptor (α2-AR) agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Brimonidine-d4 D-tartrate</b></p> <p>Cat. No.: HY-B0659AS</p> <p>Brimonidine-d4 (UK 14304-d4) D-tartrate is the deuterium labeled Brimonidine D-tartrate.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>BRL 37344 sodium</b>  <b>(BRL 37344A)</b></p> <p>Cat. No.: HY-101325</p> <p>BRL 37344 sodium (BRL 37344A) is a specific <b>β3-adrenergic</b> receptor agonist. BRL 37344 sodium treatment significantly lowers the body weight of obese mice.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg</p>
<p><b>Brombuterol D9</b>  <b>(Brombuterol D9)</b></p> <p>Cat. No.: HY-131104S</p> <p>Brombuterol D9 (Brombuterol D9) is a deuterium labeled Brombuterol. Brombuterol is a <b>β-adrenergic</b> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Brombuterol D9 hydrochloride</b>  <b>(Brombuterol D9 hydrochloride)</b></p> <p>Cat. No.: HY-131104AS</p> <p>Brombuterol D9 hydrochloride (Brombuterol D9 hydrochloride) is a deuterium labeled Brombuterol hydrochloride. Brombuterol hydrochloride is a <b>β-adrenergic</b> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Brombuterol hydrochloride</b> (Bromobuterol hydrochloride)</p> <p>Brombuterol hydrochloride (Bromobuterol hydrochloride) is a <b><math>\beta</math>-adrenergic receptor</b> agonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Bromchlorbuterol hydrochloride</b></p> <p>Bromchlorbuterol hydrochloride is an active <b><math>\beta</math>-adrenergic agonist (<math>\beta</math>-agonist)</b> and can be used for the research of pulmonary disease and asthma.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Bucindolol</b></p> <p>Bucindolol is a <b><math>\beta</math>1-adrenergic receptor</b> blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.</p>  <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>	<p><b>Bufuralol hydrochloride</b> (Ro 3-4787 hydrochloride)</p> <p>Bufuralol hydrochloride (Ro 3-4787 hydrochloride) is a potent non-selective, orally active <b><math>\beta</math>-adrenoceptor</b> antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate.</p>  <p><b>Purity:</b> <math>\geq</math>99.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>
<p><b>Bunazosin</b></p> <p>Bunazosin is a potent and selective <b><math>\alpha</math>1-adrenoceptor</b> antagonist. Bunazosin can be used for antihypertensive and ocular hypotensive research.</p>  <p><b>Purity:</b> 98.52% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Bupranolol</b></p> <p>Bupranolol is an orally active, competitive and non-selective <b><math>\beta</math>-adrenoceptor</b> antagonist without intrinsic sympathomimetic activity.</p>  <p><b>Purity:</b> 99.44% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 25 mg</p>
<p><b>Bupranolol-d9</b></p> <p>Bupranolol-d9 is the deuterium labeled Bupranolol. Bupranolol is an orally active, competitive and non-selective <b><math>\beta</math>-adrenoceptor</b> antagonist without intrinsic sympathomimetic activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Butyryltimolol</b></p> <p>Butyryltimolol, an effective prodrug of Timolol, improves the corneal penetration of Timolol. Butyryltimolol is a <b><math>\beta</math>-adrenergic</b> blocker.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Carazolol</b> (<math>\pm</math>)-Carazolol; DL-Carazolol; Suacron)</p> <p>Carazolol is a <b><math>\beta</math>1/<math>\beta</math>2 adrenoceptor</b> antagonist of high potency used in the research of hypertension. Carazolol is also a potent, selective <b><math>\beta</math>3-adrenoceptor</b> agonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Carteolol hydrochloride</b> (OPC-1085 hydrochloride)</p> <p>Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.</p>  <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>











<p><b>Carteolol-d9 hydrochloride</b> (OPC-1085-d9 hydrochloride)</p>	<p><b>Cat. No.:</b> HY-17495AS</p>
<p>Carteolol-d9 (OPC-1085-d9) hydrochloride is the deuterium labeled Carteolol hydrochloride. Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	
<p><b>Carvedilol phosphate hemihydrate</b> (BM 14190 phosphate hemihydrate)</p>	<p><b>Cat. No.:</b> HY-B0006A</p>
<p>Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective <math>\beta/\alpha</math>-1 blocker. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an <math>IC_{50}</math> of 5 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	
<p><b>Carvedilol-d4</b> (BM 14190-d4)</p>	<p><b>Cat. No.:</b> HY-B0006S1</p>
<p>Carvedilol-d4 (BM 14190-d4) is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective <math>\beta/\alpha</math>-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an <math>IC_{50}</math> of 5 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	
<p><b>Carvedilol-d5</b> (BM 14190-d5)</p>	<p><b>Cat. No.:</b> HY-B0006S2</p>
<p>Carvedilol-d5 is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective <math>\beta/\alpha</math>-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an <math>IC_{50}</math> of 5 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	
<p><b>Carvedilol-d3</b></p>	<p><b>Cat. No.:</b> HY-B0006S</p>
<p>AA is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective <math>\beta/\alpha</math>-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an <math>IC_{50}</math> of 5 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	
<p><b>Celiprolol hydrochloride</b></p>	<p><b>Cat. No.:</b> HY-B1264</p>
<p>Celiprolol hydrochloride is a potent, selective and orally active antagonist of <math>\beta</math>1-adrenoceptor with partial <math>\beta</math>2 agonist activity, therefore it is a selective adrenoceptor modulator (SAM). Celiprolol hydrochloride demonstrates antihypertensive and antianginal activity.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	
<p><b>Centanafadine hydrochloride</b> (EB-1020 hydrochloride)</p>	<p><b>Cat. No.:</b> HY-16736A</p>
<p>Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with <math>IC_{50}</math>s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter, respectively.</p> <p><b>Purity:</b> 99.93% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	
<p><b>Centanafadine</b> (EB-1020)</p>	<p><b>Cat. No.:</b> HY-16736</p>
<p>Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with <math>IC_{50}</math>s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 1 mg, 5 mg</p>	
<p><b>Centanafadine-d7 hydrochloride</b> (EB-1020-d7 hydrochloride)</p>	<p><b>Cat. No.:</b> HY-16736AS</p>
<p>Centanafadine-d7 (EB-1020-d7) hydrochloride is the deuterium labeled Centanafadine hydrochloride.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	











<p><b>CGP 20712 A</b> (CGP 20712 mesylate)</p>	<p><b>Cicloprolol hydrochloride</b></p>
<p>Cat. No.: HY-101355B</p> <p>CGP 20712 A (CGP 20712 mesylate) is a highly selective <math>\beta_1</math>-adrenoceptor antagonist with an <math>IC_{50}</math> of 0.7 nM. CGP 20712 A exhibits ~10,000-fold selectivity over <math>\beta_2</math>-adrenoceptors.</p>  <p><b>Purity:</b> <math>\geq 98.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p>Cat. No.: HY-U00066</p> <p>Cicloprolol is a partial <math>\beta_1</math>-adrenoceptor agonist.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Cimbuterol-D9</b></p>	<p><b>CL 316243</b></p>
<p>Cat. No.: HY-131105S</p> <p>Cimbuterol-D9 is the deuterium labeled Cimbuterol. Cimbuterol is a <math>\beta</math>-adrenoceptor agonist.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p>Cat. No.: HY-116771A</p> <p>CL316243 is a highly potent selective <math>\beta_3</math>-adrenoceptor agonist with a <math>EC_{50}</math> of 3 nM, but is an extremely poor to <math>\beta_1/2</math>-receptors.</p>  <p><b>Purity:</b> 98.57% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>
<p><b>Clenproperol</b></p>	<p><b>Clenproperol-D7</b></p>
<p>Cat. No.: HY-100699</p> <p>Clenproperol is a <math>\beta_2</math>-adrenergic agonist.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Cat. No.: HY-100699S</p> <p>Clenproperol-D7 is the deuterium labeled Clenproperol. Clenproperol is a <math>\beta_2</math>-adrenergic agonist.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Clonidine</b></p>	<p><b>Clonidine hydrochloride</b></p>
<p>Cat. No.: HY-12721</p> <p>Clonidine is an <math>\alpha_2</math>-adrenergic agonist.</p>  <p><b>Purity:</b> 99.93% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>	<p>Cat. No.: HY-B0409A</p> <p>Clonidine hydrochloride is an agonist of <math>\alpha_2</math>-adrenoceptor and potent antihypertensive agent.</p>  <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>
<p><b>Clonidine-d4 hydrochloride</b></p>	<p><b>Clorprenaline</b></p>
<p>Cat. No.: HY-12721S</p> <p>Clonidine-d4 hydrochloride is the deuterium labeled Clonidine. Clonidine hydrochloride is an <math>\alpha_2</math>-adrenergic agonist.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p>Cat. No.: HY-134577</p> <p>Clorprenaline is a potent agonist of <math>\beta_2</math>-adrenergic. Clorprenaline promotes animal muscular mass growth and decreases fat accumulation. Clorprenaline is a potential new lean meat-boosting feed additive.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Clorprenaline D7</b></p> <p style="text-align: right;">Cat. No.: HY-131106S</p> <p>Clorprenaline D7 is a deuterium labeled Clorprenaline. Clorprenaline is a <b><math>\beta_2</math>-adrenergic receptor</b> agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Clorprenaline hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-B1347</p> <p>Clorprenaline hydrochloride is a <b><math>\beta_2</math>-adrenergic receptor</b> agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.</p>  <p style="text-align: center;">H-Cl</p> <p><b>Purity:</b> 99.59%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>
<p><b>D2343</b></p> <p style="text-align: right;">Cat. No.: HY-U00206</p> <p>D2343 is a <b><math>\beta_2</math>-adrenoceptor</b> agonist and also is an <b><math>\alpha_1</math>-adrenoceptor</b> inhibitor.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Dabuzalgron</b> (Ro 115-1240)</p> <p style="text-align: right;">Cat. No.: HY-117071</p> <p>Dabuzalgron (Ro 115-1240) is an orally active and selective <b><math>\alpha_1A</math> adrenergic receptor</b> agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.</p>  <p><b>Purity:</b> 98.72%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>
<p><b>Dapiprazole hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-A0142A</p> <p>Dapiprazole hydrochloride is a potent <math>\alpha</math>-adrenergic blocking drug, which is used to reverse mydriasis after eye examination.</p>  <p style="text-align: center;">H-Cl</p> <p><b>Purity:</b> 99.44%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Denopamine</b> (R)-(-)-Denopamine; TA-064)</p> <p style="text-align: right;">Cat. No.: HY-119515</p> <p>Denopamine ((R)-(-)-Denopamine) is an orally active, selective <b><math>\beta_1</math>-adrenergic</b> agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-<math>\alpha</math> production in the heart. Cardiovascular effects.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Derigidole</b> (SL 86-0715)</p> <p style="text-align: right;">Cat. No.: HY-101683</p> <p>Derigidole is a peripheral <b>adrenoceptor</b> antagonist with a high affinity for <math>\alpha_2</math>-adrenoceptors.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Detomidine</b></p> <p style="text-align: right;">Cat. No.: HY-B0163</p> <p>Detomidine, an imidazole derivative, is a potent <b><math>\alpha_2</math>-adrenergic</b> agonist. Detomidine produces dose-dependent analgesic effects.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 5 mg, 10 mg, 25 mg</p>
<p><b>Detomidine carboxylic acid</b></p> <p style="text-align: right;">Cat. No.: HY-135895</p> <p>Detomidine carboxylic acid is the major urinary metabolite of Detomidine. Detomidine is a synthetic <b><math>\alpha_2</math>-adrenergic</b> agonist. Detomidine also has cardiac and respiratory effects and an antidiuretic action.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Detomidine hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-B0163A</p> <p>Detomidine hydrochloride, an imidazole derivative, is a potent <b><math>\alpha_2</math>-adrenergic</b> agonist. Detomidine hydrochloride produces dose-dependent analgesic effects.</p>  <p style="text-align: center;">HCl</p> <p><b>Purity:</b> 99.82%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>











<p><b>Dexmedetomidine</b> (+)-Medetomidine; (S)-Medetomidine</p> <p>Cat. No.: HY-12719</p> <p>Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of <math>\alpha_2</math>-adrenoceptor, with a <math>K_i</math> of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against <math>\alpha_1</math>-adrenoceptor.</p> <p><b>Purity:</b> 99.63% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg</p> 	<p><b>Dexmedetomidine hydrochloride</b> ((+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride)</p> <p>Cat. No.: HY-17034A</p> <p>Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of <math>\alpha_2</math>-adrenoceptor, with a <math>K_i</math> of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against <math>\alpha_1</math>-adrenoceptor.</p> <p><b>Purity:</b> 99.39% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p> 
<p><b>Dexmedetomidine-13C,d3 hydrochloride</b> ((+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)</p> <p>Cat. No.: HY-17034AS</p> <p>Dexmedetomidine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of <math>\alpha_2</math>-adrenoceptor, with a <math>K_i</math> of 1.08 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Diacetolol D7</b></p> <p>Cat. No.: HY-100635S</p> <p>Diacetolol D7 is a deuterium labeled Diacetolol. Diacetolol is the major metabolite of Acebutolol. Diacetolol is a <math>\beta</math>-adrenoceptor blocking and anti-arrhythmic agent.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg</p> 
<p><b>Dibenammine hydrochloride</b> (N-(2-Chloroethyl)dibenzylamine hydrochloride)</p> <p>Cat. No.: HY-128380</p> <p>Dibenammine hydrochloride is a competitive and irreversible <b>adrenergic</b> blocking agent and is known to modify the pharmacological effects of epinephrine. Dibenammine hydrochloride cause a significant increase in the rate of destruction of I-epinephrine in the mouse.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 250 mg</p> 	<p><b>Dicentrine</b></p> <p>Cat. No.: HY-N6969</p> <p>Dicentrine is a natural product isolated from the plant <i>Lindera megaphylla</i> with antihypertensive effect. Dicentrine is an <math>\alpha_1</math>-adrenoceptor antagonist which has effective against human hyperplastic prostates.</p> <p><b>Purity:</b> 99.38% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>DL-Norepinephrine hydrochloride</b></p> <p>Cat. No.: HY-N7142</p> <p>DL-Norepinephrine hydrochloride is a synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. DL-Norepinephrine hydrochloride is a neurotransmitter targets <math>\alpha_1</math> and <math>\beta_1</math> adrenoceptors, has an increasing effect...</p> <p><b>Purity:</b> 99.59% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p> 	<p><b>DL-Norepinephrine-d6 hydrochloride</b></p> <p>Cat. No.: HY-N7142S</p> <p>DL-Norepinephrine-d6 hydrochloride is the deuterium labeled DL-Norepinephrine hydrochloride.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 10 mg, 25 mg</p> 
<p><b>Dobutamine hydrochloride</b></p> <p>Cat. No.: HY-15746</p> <p>Dobutamine hydrochloride is a synthetic catecholamine that acts on <math>\alpha_1</math>-AR, <math>\beta_1</math>-AR, <math>\beta_2</math>-AR (<math>\alpha_1</math>-, <math>\beta_1</math>- and <math>\beta_2</math>-adrenoceptors). Dobutamine hydrochloride is a selective <math>\beta_1</math>-AR agonist, relatively weak activity at <math>\alpha_1</math>-AR and <math>\beta_2</math>-AR.</p> <p><b>Purity:</b> 98.86% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p> 	<p><b>Dopexamine hydrochloride</b> (FPL60278AR)</p> <p>Cat. No.: HY-U00205</p> <p>Dopexamine hydrochloride is a <math>\beta_2</math> adrenergic receptor agonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p> 













<p><b>Doxazosin</b> (UK 33274)</p>	<p><b>Doxazosin D8</b> (UK 33274 D8)</p>
<p>Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic <math>\alpha</math>1-adrenergic receptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p>Doxazosin D8 (UK 33274 D8) is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic <math>\alpha</math>1 adrenergic receptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>
<p><b>Doxazosin mesylate</b> (UK 33274 mesylate)</p>	<p><b>Dronedarone</b> (SR 33589)</p>
<p>Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic <math>\alpha</math>1-adrenergic receptors.</p>  <p><b>Purity:</b> 99.72% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>	<p>Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III <b>antiarrhythmic agent</b> for the study of atrial fibrillation (AF) and atrial flutter.</p>  <p><b>Purity:</b> 99.81% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>
<p><b>Dronedarone D6 hydrochloride</b></p>	<p><b>Ecastolol</b></p>
<p>Dronedarone D6 hydrochloride is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III <b>antiarrhythmic agent</b> for the study of atrial fibrillation (AF) and atrial flutter.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Ecastolol is a <b>beta adrenergic receptor</b> antagonist, with antianginal activities.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Efaroxan hydrochloride</b></p>	<p><b>Epanolol</b> (Visacor; ICI141292)</p>
<p>Efaroxan hydrochloride is a potent, selective and orally active <math>\alpha</math>2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan hydrochloride is a selective <b>11-Imidazoline receptor</b> antagonist. Efaroxan hydrochloride can be used for the research of cardiovascular disease.</p>  <p><b>Purity:</b> 99.94% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Epanolol (Visacor; ICI141292) is a potent <b><math>\beta</math>-adrenoceptor</b> partial agonist with a greater affinity for <math>\beta</math>1- than <math>\beta</math>2-adrenoceptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Epanolol-d5</b></p>	<p><b>Esmolol hydrochloride</b></p>
<p>Epanolol-d5 (Visacor-d5) is the deuterium labeled Epanolol. Epanolol (Visacor) is a potent <b><math>\beta</math>-adrenoceptor</b> partial agonist with a greater affinity for <math>\beta</math>1- than <math>\beta</math>2-adrenoceptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	<p>Esmolol hydrochloride is a beta adrenergic receptor blocker.</p>  <p><b>Purity:</b> 99.34% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>

<p><b>Esmolol-d7 hydrochloride</b></p> <p>Cat. No.: HY-B1392S</p>	<p><b>Etilefrine</b></p> <p>Cat. No.: HY-A0144</p>
<p>Esmolol-d7 hydrochloride is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 10 mg</p>	<p>Etilefrine (3-[2-(ethylamino)-1-hydroxyethyl]phenol) is an <math>\alpha</math> adrenergic agonist. Etilefrine also is an AMPK activator. Etilefrine can be used for the research of postural hypotension.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Falintolol, (Z)-</b></p> <p>Cat. No.: HY-U00283</p>	<p><b>Fenmetozole Tosylate</b></p> <p>Cat. No.: HY-U00402</p>
<p>Falintolol, (Z)-, a new <math>\beta</math>-adrenergic antagonist, is characterized by the presence of an oxime function.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>Fenmetozole Tosylate is an antagonist of the actions of ethanol, also antagonizes <math>\alpha 2</math>-adrenergic receptor, and acts as an antidepressant drug.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Fenoterol</b> (Th-1165; Phenoterol)</p> <p>Cat. No.: HY-B0976</p>	<p><b>Fenoterol hydrobromide</b> (Th-1165a; Fenoterol hydrobromide)</p> <p>Cat. No.: HY-B0976A</p>
<p>Fenoterol (Th-1165), a sympathomimetic agent, is a selective and orally active <math>\beta 2</math>-adrenoceptor agonist. Fenoterol is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p>	<p>Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active <math>\beta 2</math>-adrenoceptor agonist.</p>  <p><b>Purity:</b> 99.71%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>
<p><b>Fenoterol-d6 hydrobromide</b></p> <p>Cat. No.: HY-B0976AS</p>	<p><b>Fenspiride-d5 hydrochloride</b></p> <p>Cat. No.: HY-A0027S</p>
<p>Fenoterol-d6 hydrobromide (Th-1165a-d6) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active <math>\beta 2</math>-adrenoceptor agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 10 mg</p>	<p>Fenspiride-d5 hydrochloride is the deuterium labeled Fenspiride hydrochloride. Fenspiride hydrochloride is an <math>\alpha</math> adrenergic and H1 histamine receptor antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 10 mg</p>
<p><b>FFN270 hydrochloride</b></p> <p>Cat. No.: HY-131007</p>	<p><b>Fiduxosin</b></p> <p>Cat. No.: HY-U00399</p>
<p>FFN270 hydrochloride, a fluorescent tracer of norepinephrine, is a fluorescent substrate of the norepinephrine and vesicular monoamine transporters.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>Fiduxosin is a potent <math>\alpha 1</math>-adrenoceptor antagonist, with <math>K_i</math> of 0.160 nM, 24.9 nM, and 0.920 nM for <math>\alpha 1a</math>-, <math>\alpha 1b</math>-, and <math>\alpha 1d</math>-adrenoceptors, respectively.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>

<p><b>G-Protein antagonist peptide</b></p> <p>Cat. No.: HY-P1376</p>	<p><b>G-Protein antagonist peptide TFA</b></p> <p>Cat. No.: HY-P1376A</p>
<p>G-Protein antagonist peptide is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide competitively and reversibly inhibits <b>M2 muscarinic receptor</b> activation of G<sub>i</sub> or G<sub>o</sub> and inhibits G<sub>s</sub> activation by β-adrenoceptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding.</p> <p><b>Purity:</b> 97.35%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Glaucine</b> (O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396)</p> <p>Cat. No.: HY-N3945</p>	<p><b>Glaucine-d6</b> (O,O-Dimethylisoboldine-d6; S-(+)-Glaucine-d6; NSC 34396-d6)</p> <p>Cat. No.: HY-N3945S</p>
<p>Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from <i>Glaucium flavum</i> Crantz with antitussive, bronchodilation and anti-inflammatory properties.</p> <p><b>Purity:</b> 99.57%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg</p>	<p>Glaucine-d6 (O,O-Dimethylisoboldine-d6) is the deuterium labeled Glaucine. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from <i>Glaucium flavum</i> Crantz with antitussive, bronchodilation and anti-inflammatory properties.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Gramine</b> (Donaxine)</p> <p>Cat. No.: HY-N0166</p>	<p><b>Guanabenz Acetate</b> (BR-750; Wy8678 acetate)</p> <p>Cat. No.: HY-B0566</p>
<p>Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active <b>adiponectin receptor (AdipoR)</b> agonist, with IC<sub>50</sub>s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse <b>β2-Adrenergic receptor (β2-AR)</b> agonist.</p> <p><b>Purity:</b> 99.63%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg</p>	<p>Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.</p> <p><b>Purity:</b> 98.39%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 500 mg</p>
<p><b>Guanfacine</b></p> <p>Cat. No.: HY-17416A</p>	<p><b>Guanfacine hydrochloride</b></p> <p>Cat. No.: HY-17416</p>
<p>Guanfacine is a selective α<sub>2A</sub> receptor agonist. Target: α<sub>2A</sub> Receptor Guanfacine is a sympatholytic. It is a selective α<sub>2A</sub> receptor agonist.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Guanfacine hydrochloride, an anti-hypertensive agent, is a selective α<sub>2A</sub>-adrenoceptor agonist with K<sub>d</sub> of 31 nM and displays 60-fold selectivity over α<sub>2B</sub>-adrenoceptors. IC<sub>50</sub> Value: 31 nM(K<sub>d</sub>) Target: Adrenergic Receptor Guanfacine is a sympatholytic.</p> <p><b>Purity:</b> 99.96%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>
<p><b>Guanfacine-d2 hydrochloride</b></p> <p>Cat. No.: HY-17416S</p>	<p><b>Guanoxabenz</b> (Hydroxyguanabenz)</p> <p>Cat. No.: HY-U00123</p>
<p>Guanfacine-d2 hydrochloride is the deuterium labeled Guanfacine hydrochloride. Guanfacine hydrochloride, an anti-hypertensive agent, is a selective α<sub>2A</sub>-adrenoceptor agonist with K<sub>d</sub> of 31 nM and displays 60-fold selectivity over α<sub>2B</sub>-adrenoceptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Guanoxabenz is an α<sub>2</sub> adrenergic receptor agonist, with a K<sub>i</sub> of 4000 nM and the fully activated form 40 nM for an α<sub>2A</sub> adrenoceptor.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>

<p><b>Guanoxabenz hydrochloride</b> (Hydroxyguanabenz hydrochloride)</p> <p>Guanoxabenz (Hydroxyguanabenz) hydrochloride is an <math>\alpha 2</math> adrenergic receptor agonist, with a <math>K_i</math> of 4000 nM and the fully activated form 40 nM for an <math>\alpha 2A</math> adrenoceptor.</p> <p><b>Purity:</b> 99.72% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-U00123A</p>  <p><b>Cat. No.:</b> HY-101392</p> <p>Harmane, a <math>\beta</math>-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for <b>11-Imidazoline receptor</b> (<math>IC_{50}</math>=30 nM) over <math>\alpha 2</math>-adrenoceptor (<math>IC_{50}</math>=18 <math>\mu</math>M).</p> <p><b>Purity:</b> 99.81% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg</p> 
<p><b>Harmane-d1</b></p> <p>Harmane-d1 is the deuterium labeled Harmane. Harmane, a <math>\beta</math>-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations.</p> <p><b>Purity:</b> 95.19% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-101392S</p>  <p><b>Cat. No.:</b> HY-101392S1</p> <p>Harmane-d2 is the deuterium labeled Harmane. Harmane, a <math>\beta</math>-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>HEAT hydrochloride</b> (BE2254 hydrochloride)</p> <p>HEAT (BE2254) hydrochloride is a selective <math>\alpha 1</math> adrenergic receptor antagonist. HEAT hydrochloride, a phenethylamine derivative, shows <math>pK_s</math> of 9, 9.1, and 8.57 for <math>\alpha 1a</math>, <math>\alpha 1b</math> and <math>\alpha 1c</math>, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-100980</p>  <p><b>Cat. No.:</b> HY-N2037</p> <p>Higenamine (Norcoclaurine), a <math>\beta 2</math>-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine (Norcoclaurine) has anti-apoptotic effects.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Phase 1 <b>Size:</b> 5 mg, 10 mg, 20 mg</p> 
<p><b>Higenamine hydrochloride</b> (Norcoclaurine hydrochloride)</p> <p>Higenamine hydrochloride (Norcoclaurine hydrochloride), a <math>\beta 2</math>-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries.</p> <p><b>Purity:</b> 99.06% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p><b>Cat. No.:</b> HY-N2037A</p>  <p><b>Cat. No.:</b> HY-50291</p> <p>HOKU-81 (4-Hydroxytulobuterol) is one of the metabolites of Tulobuterol (HY-B1810). HOKU-81 is a potent and selective <math>\beta 2</math>-adrenoceptor stimulant. HOKU-81 has bronchodilating effect.</p> <p><b>Purity:</b> <math>\geq</math>95.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 25 mg</p> 
<p><b>Hydrocortisone 17-butyrate</b> (Cortisol 17-butyrate; Hydrocortisone butyrate)</p> <p>Hydrocortisone 17-butyrate is an adrenocorticoid hormone.</p> <p><b>Purity:</b> 99.93% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg</p>	<p><b>Cat. No.:</b> HY-B0983</p>  <p><b>Cat. No.:</b> HY-13951</p> <p>ICI 118,551 (hydrochloride) is a highly selective <math>\beta 2</math> adrenergic receptor antagonist, with <math>K_s</math> of 0.7, 49.5 and 611 nM for <math>\beta 2</math>, <math>\beta 1</math> and <math>\beta 3</math> receptors, respectively.</p> <p><b>Purity:</b> 99.64% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p> 


<p><b>ICI 89406</b></p> <p>Cat. No.: HY-15726</p>	<p><b>Idazoxan hydrochloride</b> (RX 781094 hydrochloride)</p> <p>Cat. No.: HY-14561A</p>
<p>ICI 89406 is a selective <math>\beta_1</math> adrenergic receptor antagonist amenable to labelling with positron emitters, for PET.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Idazoxan hydrochloride (RX 781094 hydrochloride) is an <math>\alpha_2</math>-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs).</p>  <p><b>Purity:</b> 98.21% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg</p>
<p><b>Idazoxan-d4 hydrochloride</b> (RX 781094-d4 hydrochloride)</p> <p>Cat. No.: HY-14561AS</p> <p>Idazoxan-d4 (RX 781094-d4) hydrochloride is the deuterium labeled Idazoxan hydrochloride.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Imoxiterol</b> (RP 58802B)</p> <p>Cat. No.: HY-101585</p> <p>Imoxiterol (RP 58802B) is a <math>\beta</math>-adrenergic agonist.</p>  <p><b>Purity:</b> 93.86% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg</p>
<p><b>Indacaterol</b></p> <p>Cat. No.: HY-14299</p> <p>Indacaterol(Onbrez; Arcapta) is an ultra-long-acting <math>\beta</math>-adrenoceptor agonist. IC50 value: Target: <math>\beta</math>-adrenoceptor Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human <math>\beta_2</math> adrenoceptors with pEC50 of 8.06.</p>  <p><b>Purity:</b> 99.98% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>	<p><b>Indacaterol maleate</b> (QAB149)</p> <p>Cat. No.: HY-14299A</p> <p>Indacaterol (QAB149) maleate is an ultra-long-acting <math>\beta</math>-adrenoceptor agonist.</p>  <p><b>Purity:</b> 99.92% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>
<p><b>Indacaterol-d3</b></p> <p>Cat. No.: HY-14299S</p> <p>Indacaterol-d3 is deuterium labeled Indacaterol.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Indanidine</b></p> <p>Cat. No.: HY-101717</p> <p>Indanidine is an <math>\alpha</math>-adrenergic agonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Indoramin</b> (Indoramine; Wy 21901)</p> <p>Cat. No.: HY-12760</p> <p>Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the <math>\alpha_{1A}</math>-adrenoceptor.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Indoramin D5</b> (Indoramine D5; Wy-21901 D5)</p> <p>Cat. No.: HY-12760S</p> <p>Indoramin D5 is deuterium labeled Indoramin, which is a piperidine antiadrenergic agent.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

### Isamoltane hemifumarate

Cat. No.: HY-19578B

Isamoltane hemifumarate is a selective antagonist of 5-HT<sub>1B</sub> receptor, with an IC<sub>50</sub> of 39 nM for inhibits the binding of [<sup>25</sup>I]CYP to 5-HT<sub>1B</sub> recognition sites in rat brain membranes. Isamoltane hemifumarate is also a  $\beta$ -adrenoceptor ligand, with an IC<sub>50</sub> of 8.4 nM.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg




### Isoferulic acid

(3-Hydroxy-4-methoxycinnamic acid)

Cat. No.: HY-N0761

Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates  $\alpha$ 1-adrenergic receptors (IC<sub>50</sub>=1.4  $\mu$ M) to enhance secretion of  $\beta$ -endorphin (EC<sub>50</sub>=52.2 nM) and increase glucose use.

**Purity:** 99.92%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 100 mg




### Isometheptene mucate

Cat. No.: HY-B1666B

Isometheptene mucate, a sympathomimetic agent, is a indirect-acting adrenergic receptor agonist. Isometheptene mucate can be used for migraine research.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg




### Isoprenaline hydrochloride

(Isoproterenol hydrochloride)

Cat. No.: HY-B0468

Isoprenaline hydrochloride is a non-selective  $\beta$ -adrenergic receptor agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.

**Purity:** 99.52%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 200 mg, 1 g




### Isoxsuprine hydrochloride

Cat. No.: HY-B1270

Isoxsuprine hydrochloride is a  $\beta$ -adrenergic receptor agonist with K<sub>s</sub> of 13.65  $\mu$ M and 3.48  $\mu$ M for myometrial and placental  $\beta$ -adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.

**Purity:** 99.87%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 200 mg




### Isoxsuprine-d6 hydrochloride

Cat. No.: HY-B1270S

Isoxsuprine-d6 hydrochloride is the deuterium labeled Isoxsuprine hydrochloride. Isoxsuprine hydrochloride is a  $\beta$ -adrenergic receptor agonist with K<sub>s</sub> of 13.65  $\mu$ M and 3.48  $\mu$ M for myometrial and placental  $\beta$ -adrenergic receptor, respectively.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg




### Ivabradine hydrochloride

Cat. No.: HY-B0162A

Ivabradine hydrochloride is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker.

**Purity:** 99.87%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 10 mg, 50 mg, 100 mg, 200 mg




### Ivabradine-d3 hydrochloride

Cat. No.: HY-B0162AS1

Ivabradine D3 Hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I<sub>h</sub> inhibitor with IC<sub>50</sub> of 2.9  $\mu$ M, and used as a pure heart rate lowering agent.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg




### Ivabradine-d6 hydrochloride

Cat. No.: HY-B0162AS

Ivabradine D6 hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I<sub>h</sub> inhibitor with IC<sub>50</sub> of 2.9  $\mu$ M, and used as a pure heart rate lowering agent.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg














### JP1302 dihydrochloride











Cat. No.: HY-103213

JP1302 dihydrochloride is a selective, high affinity antagonist of the  $\alpha$ 2C-adrenoceptor ( $\alpha$ <sub>2C</sub>-adrenoceptor), with a K<sub>b</sub> value (antagonist activity) of 16 nM and a K<sub>i</sub> (binding affinity) value of 28 nM.











**Purity:** 99.83%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 5 mg, 10 mg, 50 mg, 100 mg























<p><b>Ko-3290</b></p> <p>Cat. No.: HY-101721</p>	<p><b>KUC-7322</b></p> <p>Cat. No.: HY-116169</p>
<p>Ko-3290 is an antagonist of <b><math>\beta</math>-adrenoceptor</b>, with cardioselectivity and antipolytic effects in animals.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>KUC-7322, a selective <b><math>\beta_3</math>-adrenoceptor</b> agonist, is the active form of ritobegron. Ritobegron decreases intravesical pressure with minimal effects on the cardiovascular system.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>KUL-7211 racemate</b></p> <p>Cat. No.: HY-19673A</p>	<p><b>L-765314</b></p> <p>Cat. No.: HY-101385</p>
<p>KUL-7211 racemate is the racemate of KUL-7211. KUL-7211 is a selective <b><math>\beta</math>-adrenoceptor</b> agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>L-765314 is a potent and selective <b><math>\alpha_1</math>b adrenergic receptor</b> antagonist with <math>K_i</math>s of 5.4 nM and 2.0 nM for rat and human <math>\alpha_1</math> adrenergic receptor, respectively.</p>  <p><b>Purity:</b> 99.77%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>L-771688</b></p> <p>Cat. No.: HY-U00237</p>	<p><b>L748337</b></p> <p>Cat. No.: HY-103211</p>
<p>L-771688 is a highly selective <b><math>\alpha_1</math>A-Adrenoceptor</b> antagonist with a <math>K_i</math> of <math>0.43 \pm 0.02</math> nM.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>L748337 is a potent <b><math>\beta_3</math>-adrenergic receptor</b> antagonist and displays selectivity over <math>\beta_1</math> and <math>\beta_2</math> receptors. The <math>K_i</math> values of L748337 for <math>\beta_3</math>-, <math>\beta_2</math>- and <math>\beta_1</math>-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively.</p>  <p><b>Purity:</b> 98.02%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>
<p><b>L755507</b></p> <p>Cat. No.: HY-19334</p>	<p><b>Labelalol</b> (AH5158; Sch-15719W free base)</p> <p>Cat. No.: HY-121383</p>
<p>L755507 is a potent, selective agonist of <b><math>\beta_3</math>-AR</b> with an <math>IC_{50}</math> of 35 nM. L755507 enhances the homology-directed repair (HDR)-mediated genome editing in CRISPR/Cas9 nickase system.</p>  <p><b>Purity:</b> 98.33%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg</p>	<p>Labelalol (AH5158) is an orally active selective <b><math>\alpha_1</math>- and non-selective <math>\beta</math>-adrenergic receptors</b> competitive antagonist. Labelalol, an anti-hypertensive agent, can be used for the research of cardiovascular disease, such as hypertension in pregnancy.</p>  <p><b>Purity:</b> 98.70%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mg, 25 mg</p>
<p><b>Labelalol hydrochloride</b> (AH-5158 hydrochloride; Sch-15719W)</p> <p>Cat. No.: HY-B1108</p>	<p><b>Landiolol hydrochloride</b> (ONO1101 hydrochloride)</p> <p>Cat. No.: HY-100607A</p>
<p>Labelalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.</p>  <p><b>Purity:</b> 99.96%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p>Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting <b>beta-blocker</b> (<math>\beta_1/\beta_2</math> selectivity=255:1, a half-life of 4min) acts as an <b>adrenoceptor</b> antagonist.</p>  <p><b>Purity:</b> 99.96%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>

<p><b>Latrepirdine dihydrochloride</b> (Dimebolin dihydrochloride)</p> <p>Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, <math>\alpha</math>-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-<math>\beta</math> (<math>A\beta</math>) secretion.</p> <p><b>Purity:</b> 99.75% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg</p>	<p><b>Cat. No.:</b> HY-14537</p>  <p><b>Levalbuterol</b> (<i>(R)</i>-Albuterol; (<i>(R)</i>-Salbutamol; Levosalbutamol)</p> <p>Levalbuterol (<i>(R)</i>-Albuterol; (<i>(R)</i>-Salbutamol) is a short-acting <math>\beta</math>2-adrenergic receptor agonist and the active (<i>(R)</i>-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B1675</p> 
<p><b>Levalbuterol tartrate</b> (Levosalbutamol tartrate)</p> <p>Levosalbutamol tartrate(levulbuterol) is the <i>R</i>-enantiomer of the short-acting <math>\beta</math>2-adrenergic receptor agonist salbutamol. IC50 Value: Target: <math>\beta</math>2-adrenergic receptor Levosalbutamol and salbutamol produced significantly better bronchodilator responses than placebo.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-17457</p>  <p><b>Levobetaxolol hydrochloride</b> (<i>(S)</i>-Betaxolol hydrochloride; AL-1577A)</p> <p>Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye. Levobetaxolol hydrochloride can be used for the research of glaucoma.</p> <p><b>Purity:</b> 98.53% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-B0381B</p> 
<p><b>Lidanserin</b> (ZK-33839)</p> <p>Lidanserin (ZK-33839) acts as a 5-HT<sub>2A</sub> and <math>\alpha</math><sub>1</sub>-adrenergic receptor antagonist.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 1 mg, 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-101815</p>  <p><b>Lidanserin-d6</b> (ZK-33839-d6)</p> <p>Lidanserin-d6 (ZK-33839-d6) is the deuterium labeled Lidanserin. Lidanserin (ZK-33839) acts as a 5-HT<sub>2A</sub> and <math>\alpha</math><sub>1</sub>-adrenergic receptor antagonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-101815S</p> 
<p><b>Lofexidine</b></p> <p>Lofexidine is a selective <math>\alpha</math>2-receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.</p> <p><b>Purity:</b> 99.08% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p><b>Cat. No.:</b> HY-B1052A</p>  <p><b>Lofexidine hydrochloride</b> (Baq-168; MDL-14042)</p> <p>Lofexidine (hydrochloride) is a selective <math>\alpha</math>2-receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.</p> <p><b>Purity:</b> 99.94% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p><b>Cat. No.:</b> HY-B1052</p> 
<p><b>Lofexidine-d4 hydrochloride</b></p> <p>Lofexidine-d4 hydrochloride (Baq-168-d4) is the deuterium labeled Lofexidine hydrochloride. Lofexidine hydrochloride is a selective <math>\alpha</math>2-receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-B1052S</p>  <p><b>Lubabegron</b> (LY-488756)</p> <p>Lubabegron is a potent modulator of <math>\beta</math>-adrenergic receptor (<math>\beta</math>-AR). Lubabegron demonstrates antagonistic behavior at the <math>\beta</math><sub>1</sub> and <math>\beta</math><sub>2</sub> receptor subtypes and agonistic behavior at the <math>\beta</math><sub>3</sub> receptor subtype in cattle. Lubabegron reduces NH<sub>3</sub> gas emissions from an animal or its waste.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-123012</p> 























<p><b>Lusaperidone</b> (R107474)</p> <p>Lusaperidone (R107474) is an <math>\alpha_2</math> adrenergic receptor antagonist with <math>K_s</math> of 0.13 and 0.15 nM for <math>\alpha_2A</math> and <math>\alpha_2C</math>, respectively.</p> <p><b>Purity:</b> 97.74% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 20 mg</p>	<p><b>Cat. No.:</b> HY-U00117</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>LY377604</b></p> <p>LY377604 is a human <math>\beta_3</math>-adrenergic receptor agonist with an <math>EC_{50}</math> of 2.4 nM and also a <math>\beta_1</math>- and <math>\beta_2</math>-adrenergic receptor antagonist.</p>  <p><b>Cat. No.:</b> HY-13713</p>
<p><b>Mabuterol-D9</b></p> <p>Mabuterol-D9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the <math>\beta_2</math>-adrenergic receptor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-13338S</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mapenterol hydrochloride</b></p> <p>Mapenterol hydrochloride is a type of <math>\beta_2</math>-adrenoceptor agonist.</p>  <p><b>Cat. No.:</b> HY-13643S</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Mapenterol-d6 hydrochloride</b></p> <p>Mapenterol-d6 hydrochloride is the deuterium labeled Mapenterol hydrochloride. Mapenterol hydrochloride is a type of <math>\beta_2</math>-adrenoceptor agonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 250 <math>\mu</math>g, 1 mg, 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-13643S1</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mebeverine D6 Hydrochloride</b></p> <p>Mebeverine D6 Hydrochloride is the deuterium labeled Mebeverine, which is an antimuscarinic.</p>  <p><b>Cat. No.:</b> HY-A0078S</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Medetomidine</b></p> <p>Medetomidine(Domtor) is a potent, highly selective <math>\alpha_2</math>-adrenoceptor agonist (<math>K_i</math> values are 1.08 and 1750 nM for <math>\alpha_2</math>- and <math>\alpha_1</math>-adrenoceptors respectively).</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p>	<p><b>Cat. No.:</b> HY-17034</p>  <p><b>Purity:</b> 99.88% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p><b>Medetomidine hydrochloride</b> (MPV785)</p> <p>Medetomidine hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic properties.</p>  <p><b>Cat. No.:</b> HY-17034B</p>
<p><b>Medetomidine-d3 hydrochloride</b> (MPV785-d3)</p> <p>Medetomidine-d3 hydrochloride (MPV785-d3) is the deuterium labeled Medetomidine hydrochloride. Medetomidine hydrochloride is an agonist of adrenergic alpha-2 receptor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-17034BS</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Meranzin</b></p> <p>Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2-BDNF signaling pathway.</p> 











<p><b>Metaproterenol</b> (Orciprenaline)</p> <p>Cat. No.: HY-B1276A</p> <p>Metaproterenol (Orciprenaline) is a direct-acting sympathomimetic and a <b><math>\beta</math>2-adrenergic receptor (<math>\beta</math>2AR)</b> agonist with an <math>IC_{50}</math> of 68 nM. Metaproterenol also has anti-inflammatory activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Metaproterenol hemisulfate</b> (Orciprenaline hemisulfate)</p> <p>Cat. No.: HY-B1276</p> <p>Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a <b><math>\beta</math>2-adrenergic receptor (<math>\beta</math>2AR)</b> agonist with an <math>IC_{50}</math> of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.</p>  <p><b>Purity:</b> 99.86% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>
<p><b>Metaproterenol-d7 hemisulfate</b></p> <p>Cat. No.: HY-B1276S</p> <p>Metaproterenol-d7 (Orciprenaline-d7) hemisulfate is the deuterium labeled Metaproterenol hemisulfate. Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a <b><math>\beta</math>2-adrenergic receptor (<math>\beta</math>2AR)</b> agonist with an <math>IC_{50}</math> of 68 nM.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Metazosin</b> (Kenosin)</p> <p>Cat. No.: HY-123563</p> <p>Metazosin (Kenosin) is a potent <b><math>\alpha</math>1 adrenoceptor</b> blocker. Metazosin is an antihypertensive agent lowering blood pressure.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Methyldopa</b> (L-(-)-<math>\alpha</math>-Methyldopa; MK-351)</p> <p>Cat. No.: HY-B0225</p> <p>Methyldopa (L-(-)-<math>\alpha</math>-Methyldopa), a potent antihypertensive agent, is an alpha-adrenergic agonist (selective for <b><math>\alpha</math>2-adrenergic receptors</b>). Methyldopa is a prodrug and is metabolized (<math>\alpha</math>-Methylepinephrine) in the central nervous system.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 500 mg</p>	<p><b>Methyldopa hydrate</b> (L-(-)-<math>\alpha</math>-Methyldopa hydrate; MK-351 hydrate)</p> <p>Cat. No.: HY-B0225B</p> <p>Methyldopa hydrate (L-(-)-<math>\alpha</math>-Methyldopa hydrate), a potent antihypertensive agent, is an alpha-adrenergic agonist (selective for <b><math>\alpha</math>2-adrenergic receptors</b>). Methyldopa hydrate is a prodrug and is metabolized (<math>\alpha</math>-Methylepinephrine) in the central nervous system.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>
<p><b>Methyldopa hydrochloride</b> (L-(-)-<math>\alpha</math>-Methyldopa hydrochloride; MK-351 hydrochloride)</p> <p>Cat. No.: HY-B0225A</p> <p>Methyldopa hydrochloride (L-(-)-<math>\alpha</math>-Methyldopa hydrochloride) hydrochloride, a potent antihypertensive agent, is an alpha-adrenergic agonist (selective for <b><math>\alpha</math>2-adrenergic receptors</b>).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 500 mg</p>	<p><b>Methyldopa-d3 hydrochloride</b> (L-(-)-<math>\alpha</math>-Methyldopa-d3 hydrochloride; MK-351-d3 hydrochloride)</p> <p>Cat. No.: HY-B0225AS</p> <p>Methyldopa-d3 (hydrochloride) is deuterium labeled Methyldopa (hydrochloride). Methyldopa hydrochloride (L-(-)-<math>\alpha</math>-Methyldopa hydrochloride) hydrochloride, a potent antihypertensive agent, is an alpha-adrenergic agonist (selective for <b><math>\alpha</math>2-adrenergic receptors</b>).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Methyldopate hydrochloride</b></p> <p>Cat. No.: HY-B1696A</p> <p>Methyldopate hydrochloride is an ethyl ester hydrochloride prodrug of <math>\alpha</math>-Methyldopa (<math>\alpha</math>-MD; HY-B0225). Methyldopa (L-(-)-<math>\alpha</math>-Methyldopa) is an <math>\alpha</math>-adrenergic agonist (selective for <b><math>\alpha</math>2-adrenergic receptors</b>). Methyldopate hydrochloride has the potential for severe hypertension research.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 25 mg, 50 mg</p>	<p><b>Metipranolol</b></p> <p>Cat. No.: HY-121567</p> <p>Metipranolol is a nonselective and orally active <b><math>\beta</math>-adrenergic receptor</b> antagonist. Metipranolol can be used for hypertension and glaucoma research.</p>  <p><b>Purity:</b> 98.36% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>











<p><b>Metipranolol hydrochloride</b></p> <p>Cat. No.: HY-16316</p>	<p><b>Metoprolol</b></p> <p>Cat. No.: HY-17503</p>
<p>Metipranolol hydrochloride is a non-selective <math>\beta</math> adrenergic receptor blocking agent.</p>  <p><b>Purity:</b> 99.92%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Metoprolol (Toprol) is a selective <math>\beta_1</math> receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: <math>\beta_1</math> receptor.</p>  <p><b>Purity:</b> 99.89%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 25 mg, 50 mg, 100 mg</p>
<p><b>Metoprolol Succinate</b></p> <p>Cat. No.: HY-17503A</p> <p>Metoprolol Succinate (Toprol XL) is a selective <math>\beta_1</math> receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: <math>\beta_1</math> receptor.</p>  <p><b>Purity:</b> 99.54%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg, 200 mg, 500 mg</p>	<p><b>Metoprolol Tartrate</b></p> <p>Cat. No.: HY-17503B</p> <p>Metoprolol is a cardioselective <math>\beta_1</math>-adrenergic blocking agent. Target: <math>\beta_1</math>- adrenergic Receptor Patients took 50 mg metoprolol twice daily with weekly titration to response or 200 mg twice daily.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Metoprolol-d6 tartrate</b></p> <p>Cat. No.: HY-17503BS</p> <p>Metoprolol-d6 (tartrate) is the deuterium labeled Metoprolol (Tartrate). Metoprolol is a cardioselective <math>\beta_1</math>-adrenergic blocking agent.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p><b>Metoprolol-d7</b></p> <p>Cat. No.: HY-17503S</p> <p>Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective <math>\beta_1</math> receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 10 mg</p>
<p><b>Metoprolol-d7 hydrochloride</b></p> <p>Cat. No.: HY-17503AS</p> <p>Metoprolol-d7 hydrochloride is the deuterium labeled Metoprolol (Succinate). Metoprolol Succinate (Toprol XL) is a selective <math>\beta_1</math> receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p><b>MG 1</b></p> <p>Cat. No.: HY-U00110</p> <p>MG 1 is an <math>\alpha_1</math> adrenergic receptor antagonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Midaglizole hydrochloride</b> (<math>\pm</math>)-DG5128; DG5128)</p> <p>Cat. No.: HY-U00165</p> <p>Midaglizole hydrochloride (DG5128) is a preferential <math>\alpha_2</math>-adrenoceptor antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (<math>pK_i=6.28</math>) toward <math>\alpha_2</math>-adrenoceptor than <math>\alpha_1</math>-adrenoceptor.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mirabegron</b> (YM178)</p> <p>Cat. No.: HY-14773</p> <p>Mirabegron is a selective <math>\beta_3</math>-adrenoceptor agonist with EC<sub>50</sub> of 22.4 nM.</p>  <p><b>Purity:</b> 99.79%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

<p><b>Mirtazapine</b> (Org3770; 6-Azamienserin)</p> <p>Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, histamine H<sub>1</sub> receptor and <math>\alpha</math>2-adrenoceptor antagonist with pK<sub>i</sub> values of 8.05, 8.1, 9.3 and 6.95, respectively.</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg, 200 mg, 500 mg</p>	<p><b>Mirtazapine-d4</b> (Org3770-d4; 6-Azamienserin-d4)</p> <p>Mirtazapine-d4 is deuterium labeled Mirtazapine. Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Moxisylyte hydrochloride</b> (Thymoxamine hydrochloride)</p> <p>Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents.</p> <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg, 1 g</p>	<p><b>N-5984</b> (KRP-204)</p> <p>N-5984 (KRP-204) is a potent and selective agonist of <math>\beta</math>3-adrenergic receptor. N-5984 has the potential for developing as one of the clinically effective drugs for obesity and diabetes mellitus.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Nadolol</b> (SQ-11725)</p> <p>Nadolol (SQ-11725) is a non-selective and orally active <math>\beta</math>-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the potential for high blood pressure, angina pectoris and vascular headaches research.</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 250 mg, 500 mg</p>	<p><b>Nadolol-d9</b> (SQ-11725-d9)</p> <p>Nadolol D9 (SQ-11725 D9) is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active <math>\beta</math>-adrenergic receptors blocker.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Naftopidil</b> (KT-611; BM-15275)</p> <p>Naftopidil (KT-611) is a selective <b>alpha1-adrenoceptor</b> antagonist, with K<sub>s</sub> of 3.7 nM, 20 nM and 1.2 nM for the cloned human <math>\alpha_{1a}</math>-, <math>\alpha_{1b}</math>- and <math>\alpha_{1d}</math>-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects.</p> <p><b>Purity:</b> 98.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g</p>	<p><b>Naftopidil dihydrochloride</b> (KT-611 dihydrochloride; BM-15275 dihydrochloride)</p> <p>Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective <b>alpha1-adrenoceptor</b> antagonist, with K<sub>s</sub> of 3.7 nM, 20 nM and 1.2 nM for the cloned human <math>\alpha_{1a}</math>-, <math>\alpha_{1b}</math>- and <math>\alpha_{1d}</math>-adrenoceptor subtypes, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Naftopidil hydrochloride</b> (KT-611 hydrochloride; BM-15275 hydrochloride)</p> <p>Naftopidil hydrochloride (KT-611 hydrochloride) is a selective <b>alpha1-adrenoceptor</b> antagonist, with K<sub>s</sub> of 3.7 nM, 20 nM and 1.2 nM for the cloned human <math>\alpha_{1a}</math>-, <math>\alpha_{1b}</math>- and <math>\alpha_{1d}</math>-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Phase 4 <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Naftopidil-d3</b> (KT-611-d3; BM-15275-d3)</p> <p>Naftopidil-d3 (KT-611-d3) is the deuterium labeled Naftopidil. Naftopidil (KT-611) is a selective <b>alpha1-adrenoceptor</b> antagonist, with K<sub>s</sub> of 3.7 nM, 20 nM and 1.2 nM for the cloned human <math>\alpha_{1a}</math>-, <math>\alpha_{1b}</math>- and <math>\alpha_{1d}</math>-adrenoceptor subtypes, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>











<p><b>Naftopidil-d5</b> (KT-611-d5; BM-15275-d5)</p> <p>Naftopidil-d5 is deuterium labeled Naftopidil. Naftopidil (KT-611) is a selective <math>\alpha</math>1a-adrenoceptor antagonist, with <math>K_{i}</math>s of 3.7 nM, 20 nM and 1.2 nM for the cloned human <math>\alpha</math>1a-, <math>\alpha</math>1b- and <math>\alpha</math>1d-adrenoceptor subtypes, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B0391S1</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-101822</p> 
<p><b>Naphazoline hydrochloride</b></p> <p>Naphazoline hydrochloride is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine. Target: Adrenergic Receptor Naphazoline hydrochloride is the common name for 2-(1-naphthylmethyl)-2-imidazoline hydrochloride.</p> <p><b>Purity:</b> 98.56% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g, 10 g</p>	<p><b>Cat. No.:</b> HY-B0446</p>  <p><b>HCl</b></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-120802</p> 
<p><b>Navafenterol saccharinate</b> (AZD-8871 saccharinate; LAS191351 saccharinate)</p> <p>Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/beta2-agonist (MABA) with long-lasting effects and favorable safety profile.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-120802A</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B0203</p> 
<p><b>Nebivolol hydrochloride</b> (R 065824 hydrochloride)</p> <p>Nebivolol hydrochloride selectively inhibits <math>\beta</math>1-adrenergic receptor with <math>IC_{50}</math> of 0.8 nM. Target: <math>\beta</math>1-adrenergic receptor Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent manner.</p> <p><b>Purity:</b> 99.82% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-B0203A</p>  <p><b>HCl</b></p> <p><b>Purity:</b> 99.02% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p><b>Cat. No.:</b> HY-B1396</p> 
<p><b>Nefazodone-d6 dihydrochloride</b> (BMJ-13754-d6 dihydrochloride; MJ-13754-1-d6 dihydrochloride)</p> <p>Nefazodone-d6 (dihydrochloride) is deuterium labeled Nefazodone (hydrochloride).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B1396S1</p>  <p><b>HCl HCl</b></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B1396S</p> 

<p><b>Neldazosin</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-106416</p> <p>Neldazosin is a potent <b>alpha1-adrenoceptor</b> antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Nicergoline</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-B0702</p> <p>Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of <b>α<sub>1A</sub>-adrenoceptor</b>. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease.</p>  <p><b>Purity:</b> 99.62%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>
<p><b>Nicergoline-13C,d3</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-B0702S</p> <p>Nicergoline-13C,d3 is the 13C- and deuterium labeled. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α<sub>1A</sub>-adrenoceptor. Nicergoline has vasodilator effects.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Norepinephrine</b> (Levaterenol; L-Noradrenaline)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13715</p> <p>Norepinephrine (Levaterenol; L-Noradrenaline) is a potent <b>adrenergic receptor (AR)</b> agonist. Norepinephrine activates α<sub>1</sub>, α<sub>2</sub>, β<sub>1</sub> receptors.</p>  <p><b>Purity:</b> 98.08%  <b>Clinical Data:</b> Launched  <b>Size:</b> 500 mg</p>
<p><b>Norepinephrine bitartrate monohydrate</b> (Levaterenol bitartrate monohydrate; ...)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13715B</p> <p>Norepinephrine (Levaterenol; L-Noradrenaline) bitartrate monohydrate is a potent <b>adrenergic receptor (AR)</b> agonist. Norepinephrine activates α<sub>1</sub>, α<sub>2</sub>, β<sub>1</sub> receptors.</p>  <p><b>Purity:</b> 99.75%  <b>Clinical Data:</b> Launched  <b>Size:</b> 500 mg, 1 g, 5 g</p>	<p><b>Norepinephrine hydrochloride</b> (Levaterenol hydrochloride; L-Noradrenaline hydrochloride)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13715A</p> <p>Norepinephrine (Levaterenol; L-Noradrenaline) hydrochloride is a potent <b>adrenergic receptor (AR)</b> agonist. Norepinephrine activates α<sub>1</sub>, α<sub>2</sub>, β<sub>1</sub> receptors.</p>  <p><b>Purity:</b> 99.95%  <b>Clinical Data:</b> Launched  <b>Size:</b> 500 mg</p>
<p><b>Norepinephrine tartrate</b> (Levaterenol tartrate; L-Noradrenaline tartrate)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13715C</p> <p>Norepinephrine (Levaterenol; L-Noradrenaline) tartrate is a potent <b>adrenergic receptor (AR)</b> agonist. Norepinephrine tartrate activates α<sub>1</sub>, α<sub>2</sub>, β<sub>1</sub> receptors.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p><b>NRA-0160</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-101641</p> <p>NRA-0160 is a selective <b>dopamine D4 receptor</b> antagonist, with a K<sub>i</sub> value of 0.48 nM and with negligible affinity for <b>dopamine D2 receptor</b> (K<sub>i</sub>: &gt;10000 nM), <b>D3 receptor</b> (K<sub>i</sub>: 39 nM), rat <b>5-HT2A receptor</b> (K<sub>i</sub>: 180 nM) and rat <b>α1 adrenoceptor</b> (K<sub>i</sub>: 237 nM).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>O-Desmethyl Mebeverine alcohol</b> (Mebeverine metabolite O-desmethyl Mebeverine alcohol)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-G0008</p> <p>O-Desmethyl Mebeverine alcohol is a metabolite of Mebeverine, which is a potent <b>α1 receptor</b> inhibitor, causing relaxation of the gastrointestinal tract.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>O-Desmethyl Mebeverine alcohol hydrochloride</b> (Mebeverine metabolite O-desmethyl Mebeverine alcohol hydrochloride)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-G0008A</p> <p>O-Desmethyl Mebeverine alcohol hydrochloride is a metabolite of Mebeverine, which is a potent <b>α1 receptor</b> inhibitor, causing relaxation of the gastrointestinal tract.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 2 mg, 5 mg, 10 mg, 50 mg</p>

<p><b>Octopamine hydrochloride</b> (±)-p-Octopamine hydrochloride</p> <p>Cat. No.: HY-B0528A</p> <p>Octopamine ((±)-p-Octopamine) hydrochloride, a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates.</p>  <p>HCl</p> <p><b>Purity:</b> 99.28% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g</p>	<p><b>Octopamine-d4 hydrochloride</b> (±)-p-Octopamine-d4 hydrochloride</p> <p>Cat. No.: HY-B0528AS</p> <p>Octopamine-d4 ((±)-p-Octopamine-d4) hydrochloride is the deuterium labeled Octopamine hydrochloride.</p>  <p>H-Cl</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Olodaterol</b> (BI1744)</p> <p>Cat. No.: HY-14301</p> <p>Olodaterol (BI1744) is a selective, long acting <math>\beta_2</math>-adrenoceptor (<math>\beta_2</math>-AR) agonist (<math>EC_{50}</math>=0.1 nM and <math>pK_i</math>= 9.14 for human <math>\beta_2</math>-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.</p>  <p>HCl</p> <p><b>Purity:</b> 98.48% <b>Clinical Data:</b> Launched <b>Size:</b> 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Olodaterol hydrochloride</b> (BI1744 hydrochloride)</p> <p>Cat. No.: HY-14301A</p> <p>Olodaterol (BI1744) hydrochloride is a selective, long acting <math>\beta_2</math>-adrenoceptor (<math>\beta_2</math>-AR) agonist (<math>EC_{50}</math>=0.1 nM and <math>pK_i</math>= 9.14 for human <math>\beta_2</math>-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.</p>  <p>H-Cl</p> <p><b>Purity:</b> 99.70% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>OPC-28326</b></p> <p>Cat. No.: HY-101610</p> <p>OPC-28326 is a selective peripheral vasodilator and an antagonist of <math>\alpha_2</math>-adrenoceptor, with <math>K_i</math> of 2040, 285, and 55nM for <math>\alpha_2A</math>-, <math>\alpha_2B</math>- and <math>\alpha_2C</math>-adrenoceptors, respectively.</p>  <p>HCl</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Oxprenolol hydrochloride</b> (Ba 39089)</p> <p>Cat. No.: HY-B1486</p> <p>Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable <math>\beta</math>-adrenoceptor (<math>\beta</math>-AR) antagonist with a <math>K_i</math> of 7.10 nM in a radioligand binding assay using rat heart muscle.</p>  <p>H-Cl</p> <p><b>Purity:</b> 99.86% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>Oxprenolol-d7</b></p> <p>Cat. No.: HY-B1486AS</p> <p>Oxprenolol-d7 is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable <math>\beta</math>-adrenoceptor (<math>\beta</math>-AR) antagonist with a <math>K_i</math> of 7.10 nM in a radioligand binding assay using rat heart muscle.</p>  <p>HCl</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Oxprenolol-d7 hydrochloride</b> (Ba 39089-d7)</p> <p>Cat. No.: HY-B1486S</p> <p>Oxprenolol-d7 hydrochloride (Ba 39089-d7) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable <math>\beta</math>-adrenoceptor (<math>\beta</math>-AR) antagonist with a <math>K_i</math> of 7.10 nM in a radioligand binding assay using rat heart muscle.</p>  <p>H-Cl</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Paliperidone</b> (9-Hydroxyrisperidone)</p> <p>Cat. No.: HY-A0019</p> <p>Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a <b>dopamine D2</b> antagonist and <b>5-HT2A</b> antagonist. Paliperidone is also active as an antagonist at <math>\alpha_1</math> and <math>\alpha_2</math> adrenergic receptors and H1-histaminergic receptors.</p>  <p>HCl</p> <p><b>Purity:</b> 99.87% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg</p>	<p><b>Paliperidone-d4</b></p> <p>Cat. No.: HY-A0019S</p> <p>Paliperidone-d4 is the deuterium labeled Paliperidone. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a <b>dopamine D2</b> antagonist and <b>5-HT2A</b> antagonist.</p>  <p>HCl</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Pamatolol</b></p> <p>Cat. No.: HY-U00019</p>	<p><b>Pardoprunox</b> (SLV-308; DU-126891)</p> <p>Cat. No.: HY-14958</p>
<p>Pamatolol is a cardioselective <b>beta-adrenoceptor</b> antagonist without sympathomimetic activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Pardoprunox (SLV-308) is a partial <b>dopamine D2</b> and <b>D3 receptor</b> partial agonist and a <b>serotonin 5-HT1A receptor</b> agonist, with <math>pEC_{50}</math>s of 8, 9.2, and 6.3, respectively.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pardoprunox hydrochloride</b> (SLV-308 hydrochloride; DU-126891 hydrochloride)</p> <p>Cat. No.: HY-14958A</p>	<p><b>Pargolol hydrochloride</b> (Ko 1400 hydrochloride)</p> <p>Cat. No.: HY-101658</p>
<p>Pardoprunox (SLV-308) hydrochloride is a partial <b>dopamine D2</b> and <b>D3 receptor</b> partial agonist and a <b>serotonin 5-HT1A receptor</b> agonist, with <math>pEC_{50}</math>s of 8, 9.2, and 6.3, respectively.</p>  <p><b>Purity:</b> 98.24% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Pargolol hydrochloride is a <b>β adrenergic receptor</b> antagonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Paroxetine</b></p> <p>Cat. No.: HY-122272</p>	<p><b>Penbutolol sulfate</b> (-)-Terbuclomine)</p> <p>Cat. No.: HY-B1154</p>
<p>Paroxetine, a phenylpiperidine derivative, is a potent and selective <b>serotonin</b> reuptake inhibitor (SSRI). Paroxetine is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p>Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective <b>β</b> blocker. Penbutolol is a sympathomimetic drug used in the treatment of high blood pressure.</p>  <p><b>Purity:</b> 99.46% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>
<p><b>Perphenazine</b></p> <p>Cat. No.: HY-A0077</p>	<p><b>Perphenazine D8 Dihydrochloride</b></p> <p>Cat. No.: HY-A0077AS</p>
<p>Perphenazine is a typical antipsychotic drug, inhibits <b>5-HT<sub>2A</sub> receptor</b>, <b>Alpha-1A adrenergic receptor</b>, <b>Dopamine receptor D2/D3, D2L receptor</b>, and <b>Histamine H1 receptor</b>, with <math>K_i</math> values of 5.6, 10, 0.765/0.13, 3.4, and 8 nM, respectively.</p>  <p><b>Purity:</b> 99.72% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g</p>	<p>Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug (5-HT, Dopamine receptor ligand).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>PF-610355</b></p> <p>Cat. No.: HY-14296</p>	<p><b>Phenoxybenzamine (benzyl-2,3,4,5,6-d5) (hydrochloride)</b></p> <p>Cat. No.: HY-B0431AS1</p>
<p>PF-610355 is a long-acting inhaled <b>β<sub>2</sub>-adrenoceptor</b> agonist, with an <math>EC_{50}</math> of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Phenoxybenzamine (benzyl-2,3,4,5,6-d5) hydrochloride is the deuterium labeled Phenoxybenzamine hydrochloride.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>




<p><b>Phenoxybenzamine hydrochloride</b></p> <p>Cat. No.: HY-B0431A</p> <p>Phenoxybenzamine hydrochloride is a selective antagonist of both <math>\alpha</math>-adrenoceptor and calmodulin that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.</p>  <p><b>Purity:</b> <math>\geq 98.0\%</math>  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 200 mg, 500 mg, 1 g</p>	<p><b>Phenoxybenzamine-d5 hydrochloride</b></p> <p>Cat. No.: HY-B0431AS</p> <p>Phenoxybenzamine-d5 hydrochloride is the deuterium labeled Phenoxybenzamine hydrochloride.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Phentolamine mesylate</b> (Phentolamine methanesulfonate)</p> <p>Cat. No.: HY-B0362A</p> <p>Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of <math>\alpha 1</math> and <math>\alpha 2</math> adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance.</p>  <p><b>Purity:</b> 99.90%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>	<p><b>Phentolamine-d4 hydrochloride</b></p> <p>Cat. No.: HY-12717AS</p> <p>Phentolamine-d4 (Phentolamine-d4) hydrochloride is the deuterium labeled Phentolamine hydrochloride.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Phenylephrine</b> (R)-(-)-Phenylephrine; L-Phenylephrine)</p> <p>Cat. No.: HY-B0769</p> <p>(R)-(-)-Phenylephrine is a selective <math>\alpha_1</math>-adrenoceptor agonist primarily used as a decongestant.</p>  <p><b>Purity:</b> 99.52%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg</p>	<p><b>Phenylephrine hydrochloride ((R)-(-)-Phenylephrine hydrochloride; L-Phenylephrine hydrochloride)</b></p> <p>Cat. No.: HY-B0471</p> <p>(R)-(-)-Phenylephrine hydrochloride is a selective <math>\alpha_1</math>-adrenoceptor agonist with pK<sub>s</sub> of 5.86, 4.87 and 4.70 for <math>\alpha_{1D}</math>, <math>\alpha_{1B}</math> and <math>\alpha_{1A}</math> receptors respectively.</p>  <p><b>Purity:</b> 99.95%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>
<p><b>Phenylephrine-2,4,6-d3 hydrochloride</b> (R)-(-)-Phenylephrine-2,4,6-d3 hydrochloride; ...)</p> <p>Cat. No.: HY-B0471S1</p> <p>Phenylephrine-2,4,6-d3 ((R)-(-)-Phenylephrine-2,4,6-d3) hydrochloride is the deuterium labeled Phenylephrine hydrochloride.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Phenylephrine-d3 hydrochloride ((R)-(-)-Phenylephrine-d3 hydrochloride; L-Phenylephrine-d3 hydrochloride)</b></p> <p>Cat. No.: HY-B0471S</p> <p>Phenylephrine-d3 (R)-(-)-Phenylephrine-d3 hydrochloride is the deuterium labeled Phenylephrine hydrochloride. (R)-(-)-Phenylephrine hydrochloride is a selective <math>\alpha_1</math>-adrenoceptor agonist with pK<sub>s</sub> of 5.86, 4.87 and 4.70 for <math>\alpha_{1D}</math>, <math>\alpha_{1B}</math> and <math>\alpha_{1A}</math> receptors respectively.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>
<p><b>Phenylephrine-d6 hydrochloride ((R)-(-)-Phenylephrine-d6 hydrochloride; L-Phenylephrine-d6 hydrochloride)</b></p> <p>Cat. No.: HY-B0471S3</p> <p>Phenylephrine-d6 (hydrochloride) is deuterium labeled Phenylephrine (hydrochloride). (R)-(-)-Phenylephrine hydrochloride is a selective <math>\alpha_1</math>-adrenoceptor agonist with pK<sub>s</sub> of 5.86, 4.87 and 4.70 for <math>\alpha_{1D}</math>, <math>\alpha_{1B}</math> and <math>\alpha_{1A}</math> receptors respectively.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Phenylethanolamine A</b></p> <p>Cat. No.: HY-131103</p> <p>Phenylethanolamine A acts as a <math>\beta</math>-adrenoceptor agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

## Phenylethanolamine A-D3

Cat. No.: HY-131103S

Phenylethanolamine A-D3 is a deuterium labeled Phenylethanolamine A. Phenylethanolamine A acts as a  $\beta$ -adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

## Pimozide (R6238)

Cat. No.: HY-12987

Pimozide is a **dopamine receptor** antagonist, with  $K_S$  of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at  $\alpha_1$ -adrenoceptor, with a  $K_i$  of 39 nM; Pimozide also inhibits STAT3 and STAT5.




**Purity:** 99.88%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 50 mg

## Pimozide-d4 (R6238-d4)

Cat. No.: HY-12987S

Pimozide D4 (R6238 D4) is a deuterium labeled Pimozide.




**Purity:** >98%  
**Clinical Data:** Phase 4  
**Size:** 1 mg, 5 mg

## Pimozide-d5 N-Oxide

Cat. No.: HY-12987S1

Pimozide-d5 N-Oxide is the deuterium labeled Pimozide.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 10 mg

## Pindolol (LB-46)

Cat. No.: HY-B0982

Pindolol (LB-46) is a nonselective  $\beta$ -blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist ( $K_i=33$ nM).




**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 100 mg

## Pindolol-d7

Cat. No.: HY-B0982S

Pindolol-d7 (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective  $\beta$ -blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist ( $K_i=33$  nM).




**Purity:** >98%  
**Clinical Data:**  
**Size:** 2.5 mg, 1 mg, 5 mg, 10 mg, 25 mg

## Piperoxan hydrochloride (Benodaine hydrochloride)

Cat. No.: HY-100850

Piperoxan (Benodaine) hydrochloride is an  $\alpha_2$  adrenoceptor antagonist. Piperoxan hydrochloride is the first-generation antihistamine.




**Purity:** 99.39%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Piribedil

Cat. No.: HY-12707

Piribedil is a **dopamine D<sub>2</sub> receptor (D<sub>2</sub>R)** agonist which also displays antagonist property at  $\alpha_{1A}$ -adrenoceptor ( $\alpha_{1A}$ -AR).




**Purity:** 99.77%  
**Clinical Data:** Launched  
**Size:** 10 mM  $\times$  1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Piribedil D8 (ET-495 D8)

Cat. No.: HY-12707S

Piribedil D8 (ET-495 D8) is the deuterium labeled Piribedil, which is an antiparkinsonian agent.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg











## Practolol












Cat. No.: HY-119802











Practolol is a potent and selective  **$\beta_1$ -adrenergic receptor** antagonist. Practolol can be used for the research of cardiac arrhythmias.























**Purity:** 99.86%  
**Clinical Data:** No Development Reported  
**Size:** 10 mg, 25 mg, 50 mg, 100 mg











<p><b>Practolol-d7</b></p> <p style="text-align: right;">Cat. No.: HY-119802S</p> <p>(Rac)-Practolol-d7 is the deuterium labeled Practolol. Practolol is a potent and selective <b><math>\beta</math>1-adrenergic receptor</b> antagonist. Practolol can be used for the research of cardiac arrhythmias.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Prazobind</b> (SZL 49)</p> <p style="text-align: right;">Cat. No.: HY-118335</p> <p>Prazobind (SZL 49), a prazosin analog, is a potent <b>alpha 1-adrenoceptor</b> blocker. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (<math>IC_{50}=1</math> nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Prazosin</b></p> <p style="text-align: right;">Cat. No.: HY-B0193</p> <p>Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Prazosin hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-B0193A</p> <p>Prazosin hydrochloride is a well-tolerated, CNS-active <b><math>\alpha</math>1-adrenergic receptor</b> antagonist for the research of high blood pressure and alcohol use disorders.</p>  <p><b>Purity:</b> 99.93%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 200 mg, 500 mg</p>
<p><b>Prazosin-d8</b></p> <p style="text-align: right;">Cat. No.: HY-B0193S</p> <p>Prazosin D8 is the deuterium labeled Prazosin. Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Prenalterol</b></p> <p style="text-align: right;">Cat. No.: HY-112071</p> <p>Prenalterol is a selective <b><math>\beta</math>1-adrenergic receptor</b> agonist. Prenalterol has no effect on gut smooth muscle contractile activity. Prenalterol can be used for researching cardiovascular disease.</p>  <p><b>Purity:</b> 99.18%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>
<p><b>Pronethalol</b> (<math>\pm</math>)-Pronethalo)</p> <p style="text-align: right;">Cat. No.: HY-B1238</p> <p>Pronethalol (<math>\pm</math>)-Pronethalo) is a non-selective <b><math>\beta</math>-adrenergic</b> antagonist. Pronethalol is a potent inhibitor of <b>Sox2</b> expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias and limits the cerebral arteriovenous malformation (AVMs).</p>  <p><b>Purity:</b> 99.36%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Pronethalol hydrochloride</b> (<math>\pm</math>)-Pronethalo hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-B1238A</p> <p>Pronethalol (<math>\pm</math>)-Pronethalo) is a non-selective <b><math>\beta</math>-adrenergic</b> antagonist. Pronethalol is a potent inhibitor of <b>Sox2</b> expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias, and limits the cerebral arteriovenous malformation (AVMs).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 100 mg, 250 mg, 500 mg</p>
<p><b>Pronethalol-d6</b></p> <p style="text-align: right;">Cat. No.: HY-B1238S</p> <p>Pronethalol-d6 (<math>\pm</math>)-Pronethalo-d6) is the deuterium labeled Pronethalol. Pronethalol (<math>\pm</math>)-Pronethalo) is a non-selective <b><math>\beta</math>-adrenergic</b> antagonist. Pronethalol is a potent inhibitor of <b>Sox2</b> expression.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Propafenone</b> (SA-79)</p> <p style="text-align: right;">Cat. No.: HY-B0432</p> <p>Propafenone (SA-79), a <b>sodium-channel</b> blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the <b><math>\beta</math> receptor</b> (<math>IC_{50}=32</math> nM).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Propranolol</b></p> <p>Cat. No.: HY-B0573B</p> <p>Propranolol is a nonselective <math>\beta</math>-adrenergic receptor (<math>\beta</math>AR) antagonist, has high affinity for the <math>\beta</math>1AR and <math>\beta</math>2AR with <math>K_i</math> values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [<math>^3</math>H]-DHA binding to rat brain membrane preparation with an <math>IC_{50}</math> of 12 nM.</p> <p><b>Purity:</b> 99.87%  <b>Clinical Data:</b> Launched  <b>Size:</b> 100 mg</p> 	<p><b>Propranolol hydrochloride</b></p> <p>Cat. No.: HY-B0573</p> <p>Propranolol hydrochloride is a nonselective <math>\beta</math>-adrenergic receptor (<math>\beta</math>AR) antagonist, has high affinity for the <math>\beta</math>1AR and <math>\beta</math>2AR with <math>K_i</math> values of 1.8 nM and 0.8 nM, respectively.</p> <p><b>Purity:</b> 99.79%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg, 1 g</p>  <p>HCl</p>
<p><b>Propranolol-d7</b></p> <p>Cat. No.: HY-B0573BS</p> <p>Propranolol-d7 is the deuterium labeled Propranolol. Propranolol is a nonselective <math>\beta</math>-adrenergic receptor (<math>\beta</math>AR) antagonist, has high affinity for the <math>\beta</math>1AR and <math>\beta</math>2AR with <math>K_i</math> values of 1.8 nM and 0.8 nM, respectively.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 2.5 mg, 25 mg</p> 	<p><b>Propranolol-d7 (ring-d7)</b></p> <p>Cat. No.: HY-B0573S1</p> <p>Propranolol-d7 (ring-d7) is the deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective <math>\beta</math>-adrenergic receptor (<math>\beta</math>AR) antagonist, has high affinity for the <math>\beta</math>1AR and <math>\beta</math>2AR with <math>K_i</math> values of 1.8 nM and 0.8 nM, respectively.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg, 10 mg</p> 
<p><b>Propranolol-d7 hydrochloride</b></p> <p>Cat. No.: HY-B0573S</p> <p>Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective <math>\beta</math>-adrenergic receptor (<math>\beta</math>AR) antagonist, has high affinity for the <math>\beta</math>1AR and <math>\beta</math>2AR with <math>K_i</math> values of 1.8 nM and 0.8 nM, respectively.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>  <p>H-Cl</p>	<p><b>QF0301B</b></p> <p>Cat. No.: HY-101690</p> <p>QF0301B is an <math>\alpha</math>1 adrenergic receptor antagonist and a low <math>\alpha</math>2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>rac Timolol-d5 maleate</b></p> <p>Cat. No.: HY-17494S</p> <p>(Rac)-Timolol-d5 Maleate ((Rac)-L-714,465-d5 Maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic <math>\beta</math>-adrenoceptor blocker.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 10 mg</p> 	<p><b>Rauwolscine hydrochloride (<math>\alpha</math>-Yohimbine hydrochloride; Corynanthidine hydrochloride; Isoyohimbine hydrochloride)</b> Cat. No.: HY-12710A</p> <p>Rauwolscine hydrochloride is a potent and specific <math>\alpha</math>2 adrenergic receptor antagonist with a <math>K_i</math> of 12 nM.</p> <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>  <p>H-Cl</p>
<p><b>Reboxetine mesylate</b> (FCE20124 mesylate; PNU155950E mesylate)</p> <p>Cat. No.: HY-14560C</p> <p>Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a <math>K_i</math> of 8 nM.</p> <p><b>Purity:</b> 99.87%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p>  <p>relative stereochemistry</p> 	<p><b>Reproterol</b></p> <p>Cat. No.: HY-135490</p> <p>Reproterol is a dual acting <math>\beta</math>2-adrenoceptor agonist and PDE inhibitor. The theophylline constituent of Reproterol inhibits phosphodiesterase activity induced by adenylyl cyclase. Reproterol.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 











<p><b>Rilmenidine</b></p> <p>Cat. No.: HY-100490</p> <p>Rilmenidine, an innovative antihypertensive agent, is an orally active, selective <b>I1 imidazoline receptor</b> agonist. Rilmenidine is an <b>alpha 2-adrenoceptor</b> agonist. Rilmenidine induces <b>autophagy</b>.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Rilmenidine hemifumarate</b></p> <p>Cat. No.: HY-100490A</p> <p>Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective <b>I1 imidazoline receptor</b> agonist. Rilmenidine hemifumarate is an <b>alpha 2-adrenoceptor</b> agonist. Rilmenidine hemifumarate induces <b>autophagy</b>.</p> <p><b>Purity:</b> 99.82%  <b>Clinical Data:</b> Launched  <b>Size:</b> 5 mg, 10 mg</p> 
<p><b>Rilmenidine phosphate</b></p> <p>Cat. No.: HY-100490B</p> <p>Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective <b>I1 imidazoline receptor</b> agonist. Rilmenidine phosphate is an <b>alpha 2-adrenoceptor</b> agonist. Rilmenidine phosphate induces <b>autophagy</b>.</p> <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 5 mg, 10 mg, 25 mg</p> 	<p><b>Rilmenidine-d4</b></p> <p>Cat. No.: HY-100490S</p> <p>Rilmenidine-d4 is the deuterium labeled Rilmenidine. Rilmenidine, an innovative antihypertensive agent, is an orally active, selective <b>I1 imidazoline receptor</b> agonist. Rilmenidine is an <b>alpha 2-adrenoceptor</b> agonist. Rilmenidine induces <b>autophagy</b>.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Ritanserin</b> (R 55667)</p> <p>Cat. No.: HY-10791</p> <p>Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of <b>5-HT<sub>2</sub> receptor</b>, with an <b>IC<sub>50</sub></b> of 0.9 nM, less active on Histamine <b>H<sub>1</sub></b>, Dopamine <b>D<sub>2</sub></b>, Adrenergic <b>α<sub>1</sub></b>, Adrenergic <b>α<sub>2</sub></b> receptors.</p> <p><b>Purity:</b> 99.78%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM × 1 mL, 5 mg</p> 	<p><b>Ritodrine hydrochloride</b> (DU21220 hydrochloride)</p> <p>Cat. No.: HY-B0452</p> <p>Ritodrine hydrochloride (DU21220 hydrochloride) is a <b>β-2 adrenergic receptor</b> agonist. Target: <b>β-2 Adrenergic Receptor</b> Ritodrine is a tocolytic drug, used to stop premature labor.</p> <p><b>Purity:</b> 99.90%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p> 
<p><b>Ro 363</b></p> <p>Cat. No.: HY-123268</p> <p>Ro 363, an effective inotropic stimulant, is a potent and highly selective <b>β1-adrenoceptor</b> agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Ro 363 hydrochloride</b></p> <p>Cat. No.: HY-123268A</p> <p>Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective <b>β1-adrenoceptor</b> agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.</p> <p><b>Purity:</b> 95.88%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mg</p> 
<p><b>Rotigotine</b> (N-0437; N-0923)</p> <p>Cat. No.: HY-75502</p> <p>Rotigotine (N-0437; N-0923) is a full agonist of <b>dopamine receptor</b>, a partial agonist of the <b>5-HT<sub>1A</sub> receptor</b>, and an antagonist of the <b>α2B-adrenergic receptor</b>, with <b>K<sub>s</sub></b> of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine...</p> <p><b>Purity:</b> 99.98%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p> 	<p><b>Rotigotine Hydrochloride</b> (N-0923 Hydrochloride)</p> <p>Cat. No.: HY-A0007</p> <p>Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of <b>dopamine receptor</b>, a partial agonist of the <b>5-HT<sub>1A</sub> receptor</b>, and an antagonist of the <b>α2B-adrenergic receptor</b>, with <b>K<sub>i</sub></b> of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine...</p> <p><b>Purity:</b> 99.47%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg</p> 











<p><b>RS 17053 hydrochloride</b> (RS-17053)</p> <p>RS 17053 hydrochloride is a potent and selective <math>\alpha_1</math> adrenoceptor antagonist, with a <math>pK_i</math> value of 9.1 in native cell membrane and a <math>pA_2</math> value of 9.8 in functional assays.</p> <p><b>Purity:</b> 99.11% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-101336</p> 	<p><b>Salbutamol</b> (Albuterol; AH-3365)</p> <p>Salbutamol is a short-acting <math>\beta_2</math>-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).</p> <p><b>Purity:</b> 99.92% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-B1037</p> 
<p><b>Salbutamol hemisulfate</b> (Albuterol hemisulfate; AH-3365 hemisulfate)</p> <p>Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting <math>\beta_2</math> adrenergic receptor agonist Target: <math>\beta_2</math> Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and...</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-B0436</p> 	<p><b>Salbutamol-d3</b> (Albuterol-d3; AH-3365-d3)</p> <p>Salbutamol-d3 (Albuterol-d3) is the deuterium labeled Salbutamol. Salbutamol is a short-acting <math>\beta_2</math>-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).</p> <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-B10375</p> 
<p><b>Salbutamol-d9</b> (Albuterol-d9; AH-3365-d9)</p> <p>Salbutamol-d9 (Albuterol-d9) is the deuterium labeled Salbutamol. Salbutamol is a short-acting <math>\beta_2</math>-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).</p> <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 25 mg</p>	<p><b>Cat. No.:</b> HY-B103752</p> 	<p><b>Salmeterol</b> (GR33343X)</p> <p>Salmeterol (GR33343X) is a potent and selective human <math>\beta_2</math> adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human <math>\beta_2</math>, <math>\beta_1</math> and <math>\beta_3</math> adrenoceptors with <math>pEC_{50}</math>s of 9.6, 6.1, and 5.9, respectively.</p> <p><b>Purity:</b> 99.88% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-14302</p> 
<p><b>Salmeterol xinafoate</b> (GR 33343X xinafoate)</p> <p>Salmeterol (GR 33343X) xinafoate is a potent and selective human <math>\beta_2</math> adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human <math>\beta_2</math>, <math>\beta_1</math> and <math>\beta_3</math> adrenoceptors with <math>pEC_{50}</math>s of 9.6, 6.1, and 5.9, respectively.</p> <p><b>Purity:</b> 99.88% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-17453</p> 	<p><b>Salmeterol-D3</b></p> <p>Salmeterol-D3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human <math>\beta_2</math> adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human <math>\beta_2</math>, <math>\beta_1</math> and <math>\beta_3</math> adrenoceptors with <math>pEC_{50}</math>s of 9.6, 6.1, and 5.9, respectively.</p> <p><b>Purity:</b> 99.81% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-135119</p> 
<p><b>Salmeterol-d3 xinafoate</b> (GR 33343X-d3 xinafoate)</p> <p>Salmeterol-d3 (GR 33343X-d3) xinafoate is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human <math>\beta_2</math> adrenoceptor agonist.</p> <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-174535</p> 	<p><b>Salmeterol-d4</b></p> <p>Salmeterol-d4 is the deuterium labeled Salmeterol. Salmeterol (GR33343X) is a potent and selective human <math>\beta_2</math> adrenoceptor agonist.</p> <p><b>Purity:</b> <math>&gt;</math>98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-143025</p> 

<p><b>SB-206606</b></p> <p>Cat. No.: HY-117239</p>	<p><b>SCH 39166 hydrobromide</b> (SCH391660)</p> <p>Cat. No.: HY-110033</p>
<p>SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (<math>\beta_3</math>-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the <math>\beta_3</math>-AR than for the beta 1/beta 2-adrenergic receptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>SCH 39166 hydrobromide (SCH391660) is potent and selective antagonist of <b>dopamine D1/D5 receptor</b>, with <math>K_s</math> of 1.2 nM and 2.0 nM, respectively.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Scopine</b> (6,7-Epoxytropine)</p> <p>Cat. No.: HY-B0459</p>	<p><b>Scopine hydrochloride</b> (6,7-Epoxytropine hydrochloride)</p> <p>Cat. No.: HY-B0459A</p>
<p>Scopine is the metabolite of anisodine, which is a <math>\alpha</math>1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Scopine hydrochloride (6,7-Epoxytropine hydrochloride) is the metabolite of anisodine, which is a <math>\alpha</math>1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>
<p><b>Sertindole</b> (Lu 23-174)</p> <p>Cat. No.: HY-14543</p>	<p><b>Sertindole-d4</b></p> <p>Cat. No.: HY-14543S</p>
<p>Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, dopamine D<sub>2</sub>, and <math>\alpha</math>1 adrenergic receptors.</p>  <p><b>Purity:</b> 99.76% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p>Sertindole-d4 (Lu 23-174-d4) is the deuterium labeled Sertindole. Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> <b>Size:</b> 1 mg</p>
<p><b>Setiptiline</b> (Org-8282)</p> <p>Cat. No.: HY-32329</p>	<p><b>Setiptiline-d3</b></p> <p>Cat. No.: HY-32329S</p>
<p>Setiptiline (Org-8282) is a <b>serotonin receptor</b> antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).</p>  <p><b>Purity:</b> 96.54% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Setiptiline-d3 (Org-8282-d3) is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a <b>serotonin receptor</b> antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Sibendatet hydrochloride</b> (AR-C68397AA)</p> <p>Cat. No.: HY-124270</p>	<p><b>Silodosin</b> (KAD 3213; KMD 3213)</p> <p>Cat. No.: HY-10122</p>
<p>Sibendatet hydrochloride (AR-C68397AA) is a dual <b>D2 dopamine receptor, beta2-adrenoceptor</b> agonist with bronchodilator activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active <b><math>\alpha</math>1A-adrenergic receptor (<math>\alpha</math>1A-AR) blocker</b>.</p>  <p><b>Purity:</b> 99.87% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>

<p><b>Silodosin-d4</b></p> <p>Cat. No.: HY-101225</p> <p>Silodosin-d4 (KAD 3213-d4) is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active <math>\alpha</math>1A-adrenergic receptor (<math>\alpha</math>1A-AR) blocker.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 2.5 mg, 1 mg, 5 mg, 10 mg</p>	<p><b>Silodosin-d6</b></p> <p>Cat. No.: HY-1012251</p> <p>Silodosin-d6 is the deuterium labeled Silodosin. Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active <math>\alpha</math>1A-adrenergic receptor (<math>\alpha</math>1A-AR) blocker.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>SM-2470</b></p> <p>Cat. No.: HY-19037</p> <p>SM-2470 is a potent <math>\alpha</math>1-adrenoceptor antagonist, has sympathetic nerve activity in anesthetized rats. SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Solabegron</b> (GW 427353)</p> <p>Cat. No.: HY-19436</p> <p>Solabegron (GW 427353) is a selective <math>\beta</math><sub>3</sub>-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human <math>\beta</math><sub>3</sub>-AR, with an EC<sub>50</sub> value of 22 nM.</p>  <p><b>Purity:</b> 99.91%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg</p>
<p><b>Spiperone hydrochloride</b> (Spiroperidol hydrochloride)</p> <p>Cat. No.: HY-B1371A</p> <p>Spiperone hydrochloride (Spiroperidol hydrochloride) is a selective dopamine D<sub>2</sub> receptor (K<sub>i</sub> values of 0.06 nM, 0.6 nM, 0.08 nM, ~350 nM, ~3500 nM for D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, D<sub>1</sub> and D<sub>5</sub> receptors, respectively) and 5-HT<sub>2A</sub>/5-HT<sub>1A</sub> receptor (K<sub>s</sub> of 1 nM/49 nM)...</p>  <p><b>Purity:</b> 99.10%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mg</p>	<p><b>Spirendolol</b> (Li 32-468; S 32-468; Substance 32468)</p> <p>Cat. No.: HY-101817</p> <p>Spirendolol is a <math>\beta</math> adrenergic receptor antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>SR59230A</b></p> <p>Cat. No.: HY-100672</p> <p>SR59230A is a potent, selective, and blood-brain barrier penetrating <math>\beta</math>3-adrenergic receptor antagonist with IC<sub>50</sub>s of 40, 408, and 648 nM for <math>\beta</math>3, <math>\beta</math>1, and <math>\beta</math>2 receptors, respectively.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	<p><b>SR59230A hydrochloride</b></p> <p>Cat. No.: HY-103200</p> <p>SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating <math>\beta</math>3-adrenergic receptor antagonist with IC<sub>50</sub>s of 40, 408, and 648 nM for <math>\beta</math>3, <math>\beta</math>1, and <math>\beta</math>2 receptors, respectively.</p>  <p><b>Purity:</b> 99.88%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>ST1936</b></p> <p>Cat. No.: HY-103110</p> <p>ST1936 is a selective, nanomolar affinity 5-HT<sub>6</sub> receptor agonist with K<sub>i</sub> values of 13 nM, 168 nM and 245 nM for human 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, and 5-HT<sub>2B</sub> receptors, respectively. ST1936 also shows moderate affinity (K<sub>i</sub> of 300 nM) for human and rat <math>\alpha</math>2 adrenergic receptor.</p>  <p><b>Purity:</b> 99.70%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>ST1936 oxalate</b></p> <p>Cat. No.: HY-103110A</p> <p>ST1936 oxalate is a selective, nanomolar affinity 5-HT<sub>6</sub> receptor agonist with K<sub>i</sub> values of 13 nM, 168 nM and 245 nM for human 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, and 5-HT<sub>2B</sub> receptors, respectively. ST1936 oxalate also shows moderate affinity (K<sub>i</sub> of 300 nM) for human and rat <math>\alpha</math>2 adrenergic receptor.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>




<p><b>Sulfinalol</b></p> <p>Cat. No.: HY-106499</p>	<p><b>Synephrine</b> (Oxedrine)</p> <p>Cat. No.: HY-N0132</p>
<p>Sulfinalol is an orally active <math>\beta</math>-adrenoceptor antagonist with direct vasodilator activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Synephrine (Oxedrine), an alkaloid, is an <math>\alpha</math>-adrenergic and <math>\beta</math>-adrenergic agonist derived from the Citrus aurantium. Synephrine is a sympathomimetic compound and can be used for weight loss.</p>  <p><b>Purity:</b> 98.72% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>
<p><b>Synephrine hemitartrate</b> (Oxedrine hemitartrate)</p> <p>Cat. No.: HY-N0132B</p>	<p><b>Synephrine hydrochloride</b> (Oxedrine hydrochloride)</p> <p>Cat. No.: HY-N0132A</p>
<p>Synephrine (Oxedrine) hemitartrate, an alkaloid, is an <math>\alpha</math>-adrenergic and <math>\beta</math>-adrenergic agonist derived from the Citrus aurantium. Synephrine hemitartrate is a sympathomimetic compound and can be used for weight loss.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p>Synephrine (Oxedrine) hydrochloride, an alkaloid, is an <math>\alpha</math>-adrenergic and <math>\beta</math>-adrenergic agonist derived from the Citrus aurantium. Synephrine hydrochloride is a sympathomimetic compound and can be used for weight loss.</p>  <p><b>Purity:</b> 99.57% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>
<p><b>Talibegron hydrochloride</b> (ZD2079 hydrochloride)</p> <p>Cat. No.: HY-15378</p>	<p><b>Talipexole dihydrochloride</b> (B-HT 920 dihydrochloride)</p> <p>Cat. No.: HY-A0008</p>
<p>Talibegron hydrochloride (ZD2079 hydrochloride) is a potent <math>\beta</math>3-adrenoceptor agonist with a pD<sub>2</sub> of 3.72 on phenylephrine-precontracted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, <math>\alpha</math>2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.</p>  <p><b>Purity:</b> 99.88% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>
<p><b>Tamsulosin</b> (R)-(-)-YM12617 free base; LY253351 free base</p> <p>Cat. No.: HY-B0661</p>	<p><b>Tamsulosin hydrochloride</b> (R)-(-)-YM12617; LY253351</p> <p>Cat. No.: HY-B0661A</p>
<p>Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of <math>\alpha</math><sub>1</sub>-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models.</p>  <p><b>Purity:</b> 99.62% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of <math>\alpha</math><sub>1</sub>-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Tamsulosin-d4 hydrochloride</b> (R)-(-)-YM12617-d4; LY253351-d4</p> <p>Cat. No.: HY-B0661A51</p>	<p><b>Tamsulosin-d5 hydrochloride</b></p> <p>Cat. No.: HY-B0661A5</p>
<p>Tamsulosin-d4 (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of <math>\alpha</math><sub>1</sub>-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Tamsulosin-d5 hydrochloride is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of <math>\alpha</math><sub>1</sub>-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>TD-5471 hydrochloride</b></p> <p>Cat. No.: HY-19942A</p>	<p><b>Tedatioxetine hydrobromide</b> (Lu AA24530 hydrobromide)</p> <p>Cat. No.: HY-101755</p>
<p>TD-5471 hydrochloride is a potent and selective full agonist of the human <math>\beta_2</math>-adrenoceptor.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Tedatioxetine (Lu AA24530) hydrobromide acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub> and <math>\alpha_{1A}</math>-adrenergic receptor antagonist.</p>  <p><b>Purity:</b> 99.98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Teoprolol</b></p> <p>Cat. No.: HY-U00016</p>	<p><b>Terazosin</b></p> <p>Cat. No.: HY-B0371</p>
<p>Teoprolol is a <math>\beta</math>-adrenoceptor blocker.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Terazosin is a quinazoline derivative and a competitive and orally active <math>\alpha_1</math>-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 25 mg</p>
<p><b>Terazosin dimer impurity dihydrochloride</b></p> <p>Cat. No.: HY-131449</p>	<p><b>Terazosin hydrochloride</b></p> <p>Cat. No.: HY-B0371F</p>
<p>Terazosin dimer impurity dihydrochloride, a dimer of Terazosin, is an impurity of Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active <math>\alpha_1</math>-adrenoceptor antagonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p>Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active <math>\alpha_1</math>-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Terazosin hydrochloride dihydrate</b></p> <p>Cat. No.: HY-B0371A</p>	<p><b>Terazosin-d8</b></p> <p>Cat. No.: HY-B0371S</p>
<p>Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active <math>\alpha_1</math>-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder.</p>  <p><b>Purity:</b> 99.80% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg</p>	<p>Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active <math>\alpha_1</math>-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Terbutaline</b></p> <p>Cat. No.: HY-B0802A</p>	<p><b>Terbutaline sulfate</b> (Terbutaline hemisulfate)</p> <p>Cat. No.: HY-B0802</p>
<p>Terbutaline is a short-acting agonist of <math>\beta_2</math>-adrenoceptor (<math>\beta_2</math>-AR). Terbutaline is an active metabolite of bambuterol and used as a bronchodilator and to prevent premature labor.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p>Terbutaline sulfate is a <math>\beta_2</math>-adrenoceptor agonist; a fast-acting bronchodilator and a tocolytic to delay premature labor.</p>  <p><b>Purity:</b> 99.83% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g</p>

**Tertatolol**  
(±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol

Cat. No.: HY-U00356

Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatory effects.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg

**Tetrahydroalstonine**

Cat. No.: HY-N1163

Tetrahydroalstonine, a indole alkaloid isolated from the fruits of *Rhazya stricta*, is a selective **alpha 2-adrenoceptor** antagonist.




**Purity:** 99.95%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 1 mg, 5 mg

**Tetrahydrozoline**  
(Tetryzoline)

Cat. No.: HY-B0556

Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg

**Tetrahydrozoline hydrochloride**  
(Tetryzoline hydrochloride)

Cat. No.: HY-B0556A

Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion.




**Purity:** 99.90%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 500 mg

HCl

**Tetrahydrozoline-d4 hydrochloride**  
(Tetryzoline-d4 hydrochloride)

Cat. No.: HY-B0556AS

Tetrahydrozoline-d4 (Tetryzoline-d4) hydrochloride is the deuterium labeled Tetrahydrozoline hydrochloride. Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 10 mg

HCl

**Tiodazosin**  
(BL-5111)

Cat. No.: HY-100255

Tiodazosin is a potent competitive postsynaptic **alpha adrenergic receptor** antagonist.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

**Tizanidine**

Cat. No.: HY-B0194

Tizanidine is an **α2-adrenergic** receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg

**Tizanidine hydrochloride**

Cat. No.: HY-B0194A

Tizanidine hydrochloride is an **α2-adrenergic** receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist.




**Purity:** 99.67%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

HCl

**Tizanidine-d4**

Cat. No.: HY-B0194S

Tizanidine-d4 is the deuterium labeled Tizanidine. Tizanidine is an **α2-adrenergic** receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg, 10 mg

**Tizanidine-d4 hydrochloride**











Cat. No.: HY-B0194AS











Tizanidine-d4 (hydrochloride) is deuterium labeled Tizanidine (hydrochloride).



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

HCl

<p><b>Todalazine</b> (Ecarazine) Cat. No.: HY-B1001</p>	<p><b>Todalazine hydrochloride</b> (Ecarazine hydrochloride) Cat. No.: HY-B1001A</p>
<p>Todalazine (Ecarazine) is an anti-hypertensive agent, acts as a <math>\beta_2</math>AR blocker, with antioxidant and free radical scavenging activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p>Todalazine hydrochloride (Ecarazine hydrochloride) is an anti-hypertensive agent, acts as a <math>\beta_2</math>AR blocker, with antioxidant and free radical scavenging activity.</p>  <p><b>Purity:</b> 98.17% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>
<p><b>Tolazoline</b> (Imidaline; NSC35110) Cat. No.: HY-A0066</p>	<p><b>Tolazoline hydrochloride</b> (Imidaline hydrochloride; NSC35110 hydrochloride) Cat. No.: HY-A0066A</p>
<p>Tolazoline (Imidaline) is a non-selective competitive <math>\alpha</math>-adrenergic receptor antagonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 500 mg</p>	<p>Tolazoline (hydrochloride) (Imidaline (hydrochloride)) HCl is a non-selective competitive <math>\alpha</math>-adrenergic receptor antagonist.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g, 5 g</p>
<p><b>Trimazosin</b> Cat. No.: HY-106554</p>	<p><b>Tropodifene</b> (Tropaphen) Cat. No.: HY-U00313</p>
<p>Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows <b>hypotensive</b> effect by selectively block <math>\alpha_1</math>-adrenoceptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Tropodifene (Tropaphen) is an <math>\alpha</math>-Adrenergic receptor inhibitor.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Tulobuterol</b> (C-78 free base) Cat. No.: HY-B1810</p>	<p><b>Tulobuterol hydrochloride</b> (C-78) Cat. No.: HY-W011733</p>
<p>Tulobuterol (C-78 free base) is a long-acting <math>\beta_2</math>-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 50 mg, 100 mg</p>	<p>Tulobuterol hydrochloride (C-78) is a long-acting <math>\beta_2</math>-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.</p>  <p><b>Purity:</b> 99.69% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 500 mg</p>
<p><b>Tulobuterol-D9 hydrochloride</b> (C-78-D9) Cat. No.: HY-B1810S</p>	<p><b>Ulimorelin</b> (TZP-101) Cat. No.: HY-14903</p>
<p>Tulobuterol-D9 hydrochloride (C-78-D9) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting <math>\beta_2</math>-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p>Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an <math>EC_{50}</math> of 29 nM and a <math>K_i</math> of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at <math>\alpha_1</math>-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 1 mg, 5 mg</p>


<p><b>Urapidil</b></p> <p>Cat. No.: HY-B0716</p>	<p><b>Urapidil D6</b></p> <p>Cat. No.: HY-B0716S</p>
<p>Urapidil is an <math>\alpha_1</math> adrenoceptor antagonist and a 5-HT<sub>1A</sub> receptor agonist.</p>  <p><b>Purity:</b> 99.94%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg</p>	<p>Urapidil D6 is a deuterium labeled Urapidil. Urapidil is an <math>\alpha_1</math>-adrenoceptor antagonist and a 5-HT<sub>1A</sub> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Urapidil hydrochloride</b></p> <p>Cat. No.: HY-B0354A</p>	<p><b>Urapidil-d3</b></p> <p>Cat. No.: HY-B0716S1</p>
<p>Urapidil HCl is an <math>\alpha_1</math>-adrenoceptor antagonist and 5-HT<sub>1A</sub> receptor agonist.</p>  <p><b>Purity:</b> 98.95%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p>Urapidil-d3 is the deuterium labeled Urapidil. Urapidil is an <math>\alpha_1</math> adrenoceptor antagonist and a 5-HT<sub>1A</sub> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Urapidil-d4 hydrochloride</b></p> <p>Cat. No.: HY-B0354AS</p>	<p><b>Vanilpyruvic acid</b> (Vanilpyruvic acid)</p> <p>Cat. No.: HY-101416</p>
<p>Urapidil-d4 hydrochloride is the deuterium labeled Urapidil hydrochloride. Urapidil hydrochloride is an <math>\alpha_1</math>-adrenoceptor antagonist and 5-HT<sub>1A</sub> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b></p> <p><b>Size:</b> 1 mg, 10 mg</p>	<p>Vanilpyruvic acid is a catecholamine metabolite and precursor to vanillic acid.</p>  <p><b>Purity:</b> 98.28%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 10 mg</p>
<p><b>Vatinoxan hydrochloride</b> (MK-467 hydrochloride; L-659066 hydrochloride)</p> <p>Cat. No.: HY-19057A</p>	<p><b>Vibegron</b> (MK-4618)</p> <p>Cat. No.: HY-19933</p>
<p>Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral <math>\alpha_2</math> adrenergic receptor antagonist.</p>  <p><b>Purity:</b> 99.86%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p>Vibegron (MK-4618) is a potent, highly selective <math>\beta_3</math>-adrenoceptor agonist (EC<sub>50</sub>=1.1 nM). Vibegron can be used for severe urgency urinary incontinence related to overactive bladder.</p>  <p><b>Purity:</b> 98.82%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 5 mg, 10 mg</p>
<p><b>Vilanterol</b> (GW642444)</p> <p>Cat. No.: HY-14300</p>	<p><b>Vilanterol trifenate</b> (GW642444 trifenate)</p> <p>Cat. No.: HY-14300A</p>
<p>Vilanterol (GW642444) is a long-acting <math>\beta_2</math>-adrenoceptor (<math>\beta_2</math>-AR) agonist with 24 h activity. The pEC<sub>50</sub>s for <math>\beta_2</math>-AR, <math>\beta_1</math>-AR and <math>\beta_3</math>-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.</p>  <p><b>Purity:</b> 96.66%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Vilanterol trifenate (GW642444 trifenate) is a long-acting <math>\beta_2</math>-adrenoceptor (<math>\beta_2</math>-AR) agonist with inherent 24-hour activity. The pEC<sub>50</sub>s for <math>\beta_2</math>-AR, <math>\beta_1</math>-AR and <math>\beta_3</math>-AR are 10.37, 6.98 and 7.36, respectively.</p>  <p><b>Purity:</b> 99.20%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

<p><b>Vilanterol-d4 trifenate</b> (GW642444-d4 trifenate)</p> <p>Vilanterol-d4 (trifenate) is deuterium labeled Vilanterol (trifenate). Vilanterol trifenate (GW642444 trifenate) is a long-acting <math>\beta</math>2-adrenoceptor (<math>\beta</math>2-AR) agonist with inherent 24-hour activity. The pEC50s for <math>\beta</math>2-AR, <math>\beta</math>1-AR and <math>\beta</math>3-AR are 10.37, 6.98 and 7.36, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Xamoterol</b> (Corwin; ICI 118587)</p> <p>Xamoterol is a selective and potent agonist of <b>beta1-adrenergic receptor</b>. Xamoterol has the potential for the research of arrhythmogenesis. Xamoterol has the potential for the investigating the relationship between <math>\beta</math>1-adrenergic stimulation and IKr.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Xamoterol hemifumarate</b> (Corwin hemifumarate; ICI 118587 hemifumarate)</p> <p>Xamoterol hemifumarate is a selective and potent agonist of <b>beta1-adrenergic receptor</b>. Xamoterol hemifumarate has the potential for the research of arrhythmogenesis. Xamoterol hemifumarate has the potential for the investigating the relationship between <math>\beta</math>1-adrenergic stimulation and IKr.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>	<p><b>Xylometazoline hydrochloride</b></p> <p>Xylometazoline hydrochloride is an <math>\alpha</math>-adrenoceptor agonist commonly used as nasal decongestant.</p> <p><b>Purity:</b> 99.58% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>
<p><b>Yohimbine</b></p> <p>Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 <math>\mu</math>M.</p> <p><b>Purity:</b> 98.10% <b>Clinical Data:</b> Launched <b>Size:</b> 500 mg</p>	<p><b>Yohimbine Hydrochloride</b></p> <p>Yohimbine Hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine.</p> <p><b>Purity:</b> 99.69% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>
<p><b>Yohimbine-13C,d3</b></p> <p>Yohimbine-13C,d3 is the 13C- and deuterium labeled Yohimbine. Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC<sub>50</sub> of 0.6 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>YS-49</b></p> <p>YS-49 is a <b>PI3K/Akt</b> (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits <b>angiotensin II (Ang II)</b>-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.</p> <p><b>Purity:</b> 98.65% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>
<p><b>YS-49 monohydrate</b></p> <p>YS-49 (monohydrate) is a <b>PI3K/Akt</b> (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits <b>angiotensin II (Ang II)</b>-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.</p> <p><b>Purity:</b> 99.56% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p><b>Zilpaterol-d7</b></p> <p>Zilpaterol-d7 is a deuterium labeled Zilpaterol.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

### Zinterol (MJ 9184)

Cat. No.: HY-14304

Zinterol (MJ 9184) is a potent and selective  $\beta_2$ -adrenoceptor agonist. Zinterol increases  $I_{Ca}$  in a concentration-dependent manner with an  $EC_{50}$  of 2.2 nM.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 1 mg, 5 mg, 10 mg

### Zinterol hydrochloride (MJ 9184 hydrochloride)

Cat. No.: HY-14304A

Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective  $\beta_2$ -adrenoceptor agonist. Zinterol hydrochloride increases  $I_{Ca}$  in a concentration-dependent manner with an  $EC_{50}$  of 2.2 nM. Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits.




**Purity:**  $\geq$ 99.0%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 1 mg, 5 mg, 10 mg

### ZK-90055 hydrochloride

Cat. No.: HY-U00293

ZK-90055 hydrochloride is a  $\beta_2$  adrenergic receptor agonist.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Zotepine

Cat. No.: HY-103093

Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, Histamine H<sub>1</sub>,  $\alpha_1$ -adrenergic and Dopamine D<sub>2</sub> receptors, with K<sub>d</sub>s of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM and 8 nM, respectively. Zotepine exhibits antidepressive and anxiolytic effects in vivo.




**Purity:** 99.66%  
**Clinical Data:** No Development Reported  
**Size:** 10 mg, 25 mg, 50 mg

### $\alpha_1$ adrenoceptor-MO-1

Cat. No.: HY-U00333

$\alpha_1$  adrenoceptor-MO-1, an S enantiomer, has affinity at alpha 1 adrenergic receptor, shows alphytic activity, and possesses analgesic action; more active than R enantiomer.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### $\beta_3$ -AR agonist 1

Cat. No.: HY-101514

$\beta_3$ -AR agonist 1 (compound 15) is a highly potent, selective, and orally available  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) agonist ( $EC_{50}$ =18 nM), being inactive to  $\beta_1$ -,  $\beta_2$ -, and  $\alpha_1A$ -AR ( $\beta_1/\beta_3$ ,  $\beta_2/\beta_3$ , and  $\alpha_1A/\beta_3$ >556-fold).




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### $\beta_3$ -AR agonist 2

Cat. No.: HY-U00391

$\beta_3$ -AR agonist 2 is a potent and selective  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) agonist with an  $EC_{50}$  of 8 nM.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg